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PREFACE 
 
This doctorate is supported by Regione Emilia Romagna as a part of a Spinner PhD project coordinated 
by the University of Parma.  
The aim of the project is: 
I. Production of polymorphs, solvates, hydrates and co-crystals with green chemistry methods; 
II. Optimization of molecular and crystalline forms of drugs and pesticides in relation to activity, 
bioavailability and patentability. 
During the first and second year, we selected APIs (active pharmaceutical ingredients) in order to study 
and rationalize the relationships between crystal structure and properties of the drugs in solid state 
and solution. In the last decades, a growing interest in the solid-state properties of the drugs in addition 
to their solution chemistry has blossomed. The achievement of the desired and/or the more stable 
polymorph during the production process can be a challenge for the industry; in this sense, 
crystallization environment plays a key role in the polymorphs discrimination. 
The study of crystalline forms could be a valuable step to produce new polymorphs with better physical-
chemical properties such as solubility, permeability, thermal stability, habit, bulk density, 
compressibility, friability, hygroscopicity and dissolution rate in order to have potential industrial 
applications.  
A further way to improve these properties is the synthesis of co-crystals, i.e. solids that are crystalline 
materials composed of two or more molecules, which are in stoichiometric ratio and – as pure 
substances - are solid at ambient conditions. 
Polymorph screening and synthesis of solvates and molecular/ionic co-crystals were performed 
according to green chemistry principles (grinding, kneading in addition to the traditional methods from 
solution). Part of this project was developed in collaboration with chemical/pharmaceutical companies 
such as BASF (Germany) and UCB (Belgium). These projects focused on the one hand on the 
optimization of conditions and parameters of crystallization processes (in terms of additives, 
concentration and temperature)[Braga D. et al. Cryst. Growth Des. 2014, 14, 5729−5736; Braga D. et 
al. Cryst. Growth Des., 2014, 14(3), pp1430–1437], and on the other hand on the synthesis and 
characterization of ionic co-crystals of piracetam derivatives[Grepioni F. et al. CrystEngComm, 2014, 16, 
5887–5896]. 
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During the period of research abroad spent in Ann Arbor (University of Michigan,USA),  the stability in 
aqueous solution at the equilibrium of some ionic co-crystals (ICCs) of piracetam was investigated in 
collaboration with Professor Nair Rodriguez-Hormedo (department of Pharmaceutical Sciences).  This 
study was useful to understand the relationship between solid-state properties and those in solution, 
to design new materials that reflect some of their properties in solution. 
 
The following techniques were used for the characterization of solid products: 
(i) X-ray diffraction from single crystal (SCXRD), the ‘gold standard’ in terms of structural 
characterisation; 
(ii) X-ray powders diffraction (XRPD), provides the ‘fingerprint’ diffraction pattern characteristic of a 
crystalline solid form and, in favourable circumstances, allows structure solution or Rietveld refinement 
procedure; 
(iii) Variable Temperature X-ray powders diffraction (VTXRPD), a valuable technique to assess the 
thermal properties of crystalline solid forms;  
(iv) differential scanning calorimetry (DSC), useful in detecting phase changes with  and without change 
in mass (loss of a volatile co-crystal component and polymorphic transition/melting respectively); 
(v) thermogravimetric analysis (TG), useful in recording sample mass loss during heating process in 
order to quantify the mass loss and have indications on stoichiometry, especially in the presence of 
volatile co-crystal components; 
(vi) hot-stage microscopy (HSM), used for a visual and instrumental evaluation of the thermal processes 
and complementary to the previous techniques cited; 
(vii) measurements of dissolution rate (IDR), necessary to understand how fast is the dissolution of the 
crystalline form; 
(viii) inductive coupling plasma with optical emission as detector (ICP-OES), employed during my period 
of research abroad for quantitative measurements in solution of inorganic salts; 
(ix) UV-Spectrophotometer used during the period of research abroad used for quantitative 
measurements in solution of organic molecules. 
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In this thesis Chapter 1 introduces the concepts of crystal engineering and polymorphism and their 
effect on the pharmaceutical field in terms of the improvement of solid-state properties; Chapter 2 is 
focused on results and discussions.   
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INTRODUCTION 
 
1.1 CRYSTAL ENGINEERING 
 
In 1989, Desiraju defined crystal engineering as “the understanding of intermolecular interactions 
in the context of crystal packing and in the utilisation of such understanding in the design of new 
solids with desired physical and chemical properties”[1].  
Crystal engineering has its roots in the 1960s with G. M. J. Schmidt and its studies of solid-state 
photo-cyclization reactions [2-5], which are a bright example of supramolecular control over 
chemical properties, and are still fascinating the world of crystal engineering. Crystal engineering 
deals with design, synthesis and characterization of crystalline materials with desired properties.  
Schmidt’s work is recognized as the first attempt to rationally design crystals with a purpose [2,6]. 
It is right to point out that supramolecular chemistry [7] was crucial in the development of crystal 
engineering, a field of research that includes all traditional chemistry branches, becoming ‘‘an all-
purpose mature discipline, a science without borders, where the motivations can well be utilitarian 
and economical, but also aesthetical (when not artistic) and/or fuelled by pure, quintessential, 
scientific curiosity’’.[8]  
The aim of the design and synthesis of new crystals is to obtain supramolecular organization with 
desired properties [9-25,50] 
According to Jean-Marie Lehn, [26] supramolecular chemistry is: “chemistry beyond the molecule 
bearing on the organised entities of higher complexity that result from the association of two or 
more chemical species held together by intermolecular forces”.  
Therefore, we should think about a crystal as a supramolecular entity with a higher level of 
complexity with respect to molecules.[27,28]  
Margaret Etter [29] in 1987 wrote: “Organizing molecules into predictable arrays is the ﬁrst step in 
a systematic approach to designing organic solid-state materials”.  
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1.1.1 Crystal packing and intermolecular interactions 
 
Dunitz wrote: “A crystal is, in a sense, the supramolecule par excellence: a lump of matter, of 
macroscopic dimensions, millions of molecules long, held together in a periodic arrangement by just the 
same kind of interactions as are responsible for molecular recognition and complexation at all levels - 
ion-ion, ion-dipole, dipole-dipole interactions, hydrogen bonding, London forces, and so on”. The 
understanding and the control of intramolecular interactions is a master key in the scenario of 
supramolecular synthesis. 
In organic synthesis, but also in general, in order to develop a synthetic strategy, it is useful to 
apply a retrosynthetic approach in which the molecular structure can be simplified into a basic unit 
called synthon [30], which can be used as a synthetic tool to build complex supramolecular 
architectures.  
Scheme 1. Representative scheme of some supramolecular synthons. Reproduced from [31] 
Another useful concept, complementary to supramolecular synthons [32,33], that has become of 
considerable practical importance in crystal engineering is the tecton defined by Wuest [34] as 
moieties ‘‘whose interactions are dominated by specific attractive forces that induce the assembly 
of aggregates with controlled geometries’’.[35] 
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1.1.2 Hydrogen Bonding 
 
The hydrogen bond (HB) plays a key role in crystal engineering [36], as it is both an electrostatic 
and a directional interaction.  
Various definitions of HB have followed [37] starting from Pimentel and McClellan who claimed: “a 
hydrogen bond exists if 1) there is evidence of a bond, and 2) there is evidence that this bond sterically 
involves a hydrogen atom already bonded to another atom”[36b]. Subsequently Etter[38], from an 
elaboration of Linus Pauling’s definition, wrote: “hydrogen  bond is an interaction  that  directs  the 
association  of  a  covalently  bound   hydrogen  atom  with  one  or more  other atoms, groups of 
atoms, or molecules into  an aggregate  structure  that  is  sufficiently  stable  to  make  it convenient 
for  the  chemist  to  consider it  as  an  independent chemical  species”.  
A further interpretation defines the “classical” HB as an interaction between a donor (X-H) and an 
acceptor (Y) with X an electronegative atom and Y an electronegative and electron rich atom. [39]  
Jeffrey and Saenger [36] stated: “the use of a van der Waals distance cutoff criterion carries the 
wrong implication that hydrogen bonds become van der Waals interactions at longer distances”. 
In this sense, HB is stabilized at distances greater than the sum of the radii of vdW; the vdW 
interactions decrease more rapidly with respect to the distance (r-6) than the electrostatic 
interactions (r-1). According to Jeffrey [36], HB is considered moderate in strength if the energies are 
in the range of 4-15 kcal/mol:HB is stronger if the energy is greater than 15 kcal/mol; HB is weaker if 
the energy is less than 4 kcal/mol. [53].  
The strength of an hydrogen bond depends also on the pKa of both component involved in the bond 
and on the resonance-assisted hydrogen bonding (RAHB) mechanism [54,55]. Weak and moderate 
hydrogen bonds also play an important role in the landscape of the non-covalent interactions in the 
absence of strong HBs. The most common weak HB interactions are C-H∙∙∙N, C-H∙∙∙O, C-H∙∙∙X (X= Cl,F), 
N-H∙∙∙π …[40]. The strength of the weak HBs is directly proportional to the acidity or basicity of the 
acceptor groups like nitrogen, oxygen and halogens. 
There is no clear demarcation between strong and weak hydrogen bonds, as the strongest of the 
weakest and the weakest of the strongest have comparable energy. The distance as a parameter of 
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strength of HB interaction is one of the features to be considered; the other one is the directionality, 
indeed HB can distinguished from vdW interaction for its preference for linearity. [36, 43, 44-47]  
The presence of ionic charges on hydrogen bond acceptor and hydrogen bond donator reinforces 
the electrostatic dipole-dipole component of HB. This particular type of hydrogen bond is called 
Charge Assisted hydrogen Bond (CAHB)[41,48,49]. Charge-assisted hydrogen bonds are easily 
obtained via proton transfer in acid-base reactions and combine HB directionality with the strength 
of Coulombic forces. This type of hydrogen bond can be a valuable resource to design and 
synthesize 1D, 2D as well as 3D networks. 
1.2 POLYMORPHISM 
 
A polymorph is a solid crystalline phase of a given compound resulting from the possibility of at least 
two crystalline arrangements of the molecules of that compound in the solid state. [51]  
Polymorphism represents one of the most fascinating phenomena of solid state chemistry because of 
its intrinsic difficulties to be predicted and rationalized.[52] The relationship between nucleation phase 
and crystalline growth is often unclear, indeed there are many examples of appearing and disappearing 
polymorphs[53]. Klaproth in 1788 was the first to identify the polymorphs of calcium carbonate (calcite, 
vaterite and aragonite) [54], but crystal polymorphism was recognized with Mitscherlich only in 1823 
[55], when he observed the diﬀerence in physical and chemical properties in diﬀerent crystals of 
arsenates and phosphates.[56,57] Benzamide was the first polymorphic organic compound studied [58] 
in 1832; in the last decades, due to the surge of interest and patenting issues in the pharmaceutical, 
agrochemical and pigment industries, polymorphism has become a central field of investigation for the 
solid-state scientific community. [59-65]  
Sirota wrote in 1982: “Polymorphism is now believed to be characteristic of all substances, its actual 
non-occurance arising from the fact that a polymorphic transition lies above the melting point of the 
substance or in the area of as yet unattainable values of external equilibrium factor or other conditions 
providing for the transition”[66]. 
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1.2.1 Conformational polymorphism 
 
According to the IUPAC definition, a conformation is “the spatial arrangement of the atoms aﬀording 
distinction between stereoisomers which can be interconverted by rotations about formally single 
bonds”. On the other side, a conformer is defined as “one of a set of stereoisomers, each of which is 
characterized by a conformation corresponding to a distinct potential energy minimum”.[67] 
In 1962, Eliel stated that conformation “is used to denote any one of the inﬁnite number of momentary 
arrangements of the atoms in space that result from rotation about single bonds”.[68] in 1985, Glusker 
and Trueblood deﬁne it as “One of the likely shapes of a molecule. Generally applied to molecules for 
which there is a possibility for rotation about bonds. Diﬀerent rotational positions about bonds are 
represented by torsion angles.”[69]  
Dunitz included another component, the energy: “we can be reasonably conﬁdent that any particular 
arrangement of atoms observed in a molecular crystal cannot be far from an equilibrium structure of 
the isolated molecule. X-ray analysis thus provides information about the preferred conformations of 
molecules although it has nothing to say about the energy diﬀerences between conformations or the 
energy barriers that separate them.”[70] 
Cruz-Cabeza and Bernstein incorporated the term energy into the deﬁnition of conformer: “Any change 
in a given single rotatable bond (henceforth R- bond) of a molecule always aﬀords a new conformation, 
but it aﬀords a new conformer only if the conformational change goes through a potential energy 
barrier into a diﬀerent potential energy well. Intermolecular interactions present in organic crystals are 
generally not suﬃcient to signiﬁcantly perturb bond lengths and bond angles, but for those molecules 
that do exhibit torsional degrees of freedom, various polymorphs can exhibit diﬀerent molecular 
conformations and, more importantly, diﬀerent conformers.” [71] 
Conformers correspond to distinct energy minima of the gas-phase potential energy surface (gas-PES). 
In a crystal the energy minima correspond to the minima of the sum of the intra- and intermolecular 
energies. The presence of neighbouring molecules and the eﬀect of these molecules on the molecular 
conformations changes dramatically the environment with respect to the gas phase. When there is a 
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variation of a torsion angle, the molecule of interest has a new conformation; moreover, according to 
the authors [71], the molecule can be considered conformer if there is a noteworthy change in potential 
energy as a consequence of the new conformation. On the other hand, when ﬂexible molecules tend 
to adapt themselves to the crystal environment varying slightly their conformation, there is a small 
conformational energy penalty reflected in a “conformational adjustament”, see figure 1. 
 
Figure 1. Schematic representation of “conformational change” and “conformational adjustment” [71]. 
It is worth stressing that the high occurrence of conformational polymorphism in APIs [72] is usually 
due to and facilitated by the flexibility of molecular structures [73].   
1.2.2 Multiple crystal forms 
 
The outcome of a crystallization process is hard to predict and can consist of new polymorphs, solvates, 
hydrates, salts and co-crystals[74] as well as solid solutions[75] and eutectics[76]. All these crystal forms 
are summarized in Figure 2. 
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Figure 2. Schematic representation of the structural relationship between polymorphs, solvates, co-crystals, 
salts, amorphous, continuous and discontinuous solid solution.  
The aim of the exploration of a polymorphic system is to find the most stable form and verify the 
existance of interconverting (enantiotropism) or non interconverting (monotropism) forms as a 
function of temperature – see figure 3.  
 
 
 
 
 
 
 
 
 
 
Figure 3. Qualitative E/T diagram for a dimorphic enantiotropic system (left), and for a dimorphic monotropic 
system (right).  
 
Polymorphism can dramatically influence solubility but also other physical-chemical properties, like 
thermal and mechanical stability, permeability, hygroscopicity, habit, bulk density and so on.  
Also the synthesis and study of co-crystals has gained importance in research and innovation in 
pharmaceutical and material science fields.[77,78-81] Pharmaceutical co-crystals investigation 
represents an opportunity to produce a stable crystalline solid starting from an amorphous or hard-to-
crystallise API. Pharmaceutical co-crystal are composed by at least one API and the coformer should be 
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chosen so as to show no adverse side effects. Moreover, it should be approved by the USA Food and 
Drug Administration (FDA, for the US market)) or approved as Generally Regarded as Safe (GRAS). [82]  
Co-crystals are composed by at least two components, which are present in stoichiometric ratio and 
are solid – as pure forms – at ambient condition. The practical application of pharmaceutical co-crystals 
depends on how a co-crystal is considered: it could be considered a physical mixture (regulated by 
current compendial guidelines), or a new chemical entity [83]. In this regard, the FDA has released (April 
2013) a guidance for industry on the regulatory classification of pharmaceutical co-crystals for 
applicants for New Drug Applications (NDAs), in which is stated: “In a co-crystal, the molecular 
association between an API and its excipient(s) occurs within the same crystal lattice and is governed by 
nonionic interactions, unlike the ionic interactions required for salt formation of an API. Therefore, 
within the Agency’s current regulatory framework, co-crystals are classified as dissociable “API—
excipient” molecular complexes (with the neutral guest compound being the excipient)” [84]. In this 
sense, ionic co-crystals, [85] for which the co-former is an inorganic salt, are located in between co-
crystals and salt definitions. Moreover, we deduce from these statements that the borderline between 
co-crystal and physical mixture is not well marked and it is reflected on the fact that no commercial 
pharmaceutical co-crystals have been approved so far for sale as drug substances.  
Ideally, it is necessary to apply different methods in the research of polymorphs in order to minimize 
some risks linked to the presence of new unpredictable polymorphs, as shown by Jones and co-
workers[86] or polymorphs obtained thorough fast crystallization methods which can lead to kinetic 
polymorphs, able to transform to a more stable form upon storage. An example is given by 1,3,5-
trinitrobenzene[87]  and its elusive thermodynamic form, ignored for 125 years. 
Below are listed the most used crystallization techniques for a polymorph/multiple forms screening. 
Crystallization from solution  
Crystallization from solution is the most common method for air stable polymorph screening. It is 
performed preparing a near saturated solution with mixtures of solvents of different polarities in which 
the rate of evaporation of the solvent can be varied by changing the temperature.  
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Crystallization by thermal gradient 
This method is alternative to the previous one; the near saturated solution at high temperature is kept 
in a sealed vial and the crystallization process depends on the temperature gradient applied upon 
cooling. 
Solvent/Vapour diffusion 
This method is used with to samples that are air and/or solvent sensitive. The solid sample, pure or as 
a mixture, is exposed to solvent vapours or moisture. 
Solid-state synthesis 
As an alternative to solvent-based crystallization techniques, solid-state synthesis (manual or 
mechanical grinding) has been extensively used for crystals and co-crystals screening [88]. Grinding with 
a catalytic amount of solvent (kneading) added to the reactants can also be employed. [89] These two 
methods usually improve the reaction rate, as temperature increases upon  grinding; continuous 
contact between the different components is also achieved.  
Hydrothermal and solvothermal synthesis 
Hydrothermal or solvothermal synthesis are techniques widely used for the synthesis of inorganic or 
metal-organic material[90] but also employed for crystal and co-crystal polymorph screening. For 
example, Wang et al. applied this technique to prepare a co-crystal involving 1,2-bis(4-pyridyl)ethylene 
(BPE) and 4,4′-dihydroxybenzophenone (DHB).[91]  
High-Pressure Crystallization Process 
Fabbiani et al. described how pressure can be used to explore polymorphism, and provided examples 
of compounds studied at high pressure.[92,93]  
 
  
16 
 
REFERENCES: 
[1] G. R. Desiraju and R. Parthasarathy, J. Am. Chem. Soc.,1989, 111, 8725.                                         
[2] G. M. J. Schmidt, Pure Appl. Chem., 1971,27, 647–678.                                                                               
[3] M. D. Cohen and G. M. J. Schmidt, J. Chem. Soc., 1996-2000 (1964). 
[4] M. D. Cohen, G. M. J. Schmidt, and F. I. Sonntag, J. Chem. Soc., 2000-2013 (1964). 
[5] G. M. J. Schmidt, ibid., 2014-2021 (1964).                                                                                                                  
[6]L. R. MacGillivray, CrystEngComm,2002, 4, 37; L. R. Macgillivray, G. S. Papaefstathiou, T. Friscic, T. 
D. Hamilton, D. K. Bucar, Q. Chu, D. B. Varshney and I. G. Georgiev, Acc. Chem. Res., 2008, 41, 280–
291. 
[7] J. M. Lehn, Angew. Chem., Int. Ed. Engl., 1990, 29, 1304; J. M. Lehn, Supramolecular Chemistry: 
Concepts and Perspectives, VCH, Weinheim, 1995; J. W. Steed and J. L. Atwood, Supramolecular 
Chemistry, Wiley & Sons, 2000. 
[8] D. Braga, J. Miller, G. R. Desiraju, A. G. Orpen and S. L. Price, CrystEngComm, 2002, 4, 500. 
[9] A. I. Kitaigorodskii, Molecular Crystals and Molecules, Academic Press, New York, 1973. 
[10] J. M. Thomas, Nature 1981, 289, 633 – 634. 
[11] L. Addadi, M. Lahav, Pure Appl. Chem. 1979, 51, 1269 – 1284. 
[12] G. Wegner, Z. Naturforsch. B 1969, 24, 824 – 832. 
[13] Crystal Engineering. From Molecules and Crystals to Materials (Eds.: D. Braga, F. Grepioni, A. G. 
Orpen), Kluwer, Dordrecht, 1999. 
[14] Frontiers in Crystal Engineering (Eds.: E. R. Tiekink, J. J.Vittal), Wiley, Chichester, 2005. 
[15] C. V. K. Sharma, Cryst. Growth Des. 2002, 2, 465 – 474. 
[16] D. Braga, F. Grepioni, Chem. Commun. 2005, 3635 – 3645. 
[17] A. D. Burrows, Encyclopedia of Supramolecular Chemistry,Vol. 1 (Eds.: J. Atwood, J. Steed), 
Marcel Dekker, New York, 2004, pp. 319 – 325. 
[18] P. Coppens, S. L. Zheng, M. Gembicky, M. Messerschmidt, P. M. Dominiak, CrystEngComm 2006, 
8, 735 – 741. 
[19] R. Bishop, Synlett 1999, 1351 – 1358. 
[20] K. Biradha, CrystEngComm 2003, 5, 374 – 384. 
[21] S. A. Dalrymple, G. K. H. Shimizu, J. Mol. Struct. 2006, 796, 95 – 106. 
17 
 
[22] P. Erk, H. Hengelsberg, M. F. Haddow, R. van Gelder, CrystEngComm 2004, 6, 474 – 483. 
[23] J. M. Lehn, Angew. Chem. 1988, 100, 91 – 116; Angew. Chem. Int. Ed. Engl. 1988, 27, 89 – 112. 
[24] J. D. Dunitz, Pure Appl. Chem. 1991, 63, 177 – 185. 
[25] G. M.Whitesides, E. E. Simanek, J. P. Mathias, C. T. Seto, D. N. Chin, M. Mammen, D. M. Gordon, 
Acc. Chem. Res. 1995, 28, 37 – 44. 
[26] Nobel lecture, December 8, 1987 
[27] M. C. T. Fyfe, J. F. Stoddart, Acc. Chem. Res. 1997, 30, 393 – 401. 
[28] G. R. Desiraju, Curr. Sci. 2005, 88, 374 – 380. 
[29] Thomas W. Panunto , Zofia Urbanczyk-Lipkowska , Ruth Johnson , Margaret C. Etter J. Am. Chem. 
Soc., 1987, 109 (25), pp 7786–7797.                                                                                                          
[30] E.J.Corey, Pure Appl.Chem, 1967, 14, 19; E.J.Corey, Chem.Soc.rev. 1998, 17,111. 
[31] G. R. Desiraju, J. Chem. Soc., Dalton Trans., 2000, 3745. 
[32] M. W. Hosseini, Acc. Chem. Res., 2005, 38, 313–323; M. W. Hosseini, CrystEngComm, 2004, 6, 
318–322. 
[33] S. A. Barnett, A. J. Blake and N. R. Champness, CrystEngComm, 2003, 5, 134–136; C. B. Aakeroy, 
A. M. Beatty and B. A. Helfrich, Angew. Chem., Int. Ed., 2001, 40, 3240; C. B. Aakeroy, M. Fasulo, N. 
Schultheiss, J. Desper and C. Moore, J. Am. Chem. Soc., 2007, 129, 13772–13773. 
 
[34] P. Brunet, M. Simard and J. D. Wuest, J. Am. Chem. Soc., 1997, 119, 2737. 
[35] J. Hamblin, S. P. Argent, A. J. Blake, C. Wilson and N. R. Champness, CrystEngComm, 2008, 10, 
1782. 
[36] Braga, D.; Grepioni, F. Hydrogen Bonding Interactions with the CO-Ligand in the Solid State. Acc. 
Chem. Res. 1997, 30, 81; T. Steiner, Angew. Chem. Int. Ed. 2002, 41, 48-76; G. C. Pimentel, A. L. 
McClellan, The Hydrogen Bond, Freeman, San Francisco, 1960 ; L. Pauling, The Nature of the Chemical 
Bond, 3rd ed., Cornell University Press, Ithaca, 1963; W. C. Hamilton, J. A. Ibers, Hydrogen Bonding in 
Solids, Benjamin, New York, 1968; G. A. Jeffrey, W. Saenger, Hydrogen Bonding in Biological 
Structures, Springer, Berlin, 1991; G. A. Jeffrey, An Introduction to Hydrogen Bonding, Oxford 
University Press, Oxford, 1997; S. Scheiner, Hydrogen Bonding. A Theoretical Perspective, Oxford 
University Press, Oxford, 1997; G. R. Desiraju, T. Steiner, The Weak Hydrogen Bond in Structural 
18 
 
Chemistry and Biology, Oxford University Press, Oxford, 1999; The Hydrogen Bond (Ed.: D. Hadzi), 
Pergamon, New York, 1957; The Hydrogen Bond. Recent Developments in Theory and Experiment, 
Vols. 1-3 (Eds.: P. Schuster, G. Zundel, C. Sandorfy), North-Holland, Amsterdam, 1976; Theoretical 
Treatments of Hydrogen Bonding (Ed.: D. Hadzi),Wiley, Chichester, 1997. 
[37] Aakeroy, C. B.; Seddon, K. R. The Hydrogen Bond and Crystal Engineering. Chem. Soc. Rev. 1993, 
397. 
[38] Etter, M. C. Encoding and Decoding Hydrogen-Bond Patterns of Organic Compounds. Acc. Chem. 
Res. 1990, 23, 120. 
[39] Gordon, M. S.; Jensen, J. H. Understanding The Hydrogen Bond Using Quantum Chemistry. Acc. 
Chem. Res. 1996, 29, 536. 
[40]D.R. Armstrong, S. Bennett, M.G. Davidson, R. Snaith, D. Stalke, D.s. Wright, J.Chem.Soc. Commun. 
1992,262; M.A. Viswamitra, R.Radhakrishnan, G.R. Desiraju, J. Am. Chem. Soc. 1993, 115, 4868. 
[41] P. Gilli, V. Ferretti, V. Bertolasi, G. Gilli, J. Am. Chem. Soc 1994, 116, 909-915. 
[42] F.Fillaux, N. Leygue, J. Tomkinson, A. Cousson, W. Paulus, Chem. Phys. 1999, 244, 387-403. 
[43] J.Kroon, J.A. Kanters, Nature, 1974, 248, 667-669. 
[44] H.H.J. Savage, J. Finney, Nature 1986, 322, 717-720. 
[45] D. Braga, F. Grepioni, E. Tedesco, Organometalics 1998, 17, 2669-2672. 
[46] C.B. Aakeroy, T.A. Evans, K.R. Seddon, I. Palinko, New J. Chem. 1999, 23, 145-152; P.K. Thallapally, 
A. Nangia, CrystEngComm 2001, 27. 
[47] V.R. Thalladi, H.C. Weiss, D.Blaser, R. Boese, A. Nangia, G.R. Desiraju, J. Am. Chem. Soc. 1998, 
120, 8702-8710.  
[48] Speakman J.C. 1972 Struct Bond 12, 141. 
[49] Grabowsky S.J. 2006 Annu Rep Prop Chem Sect C, 102, 131. 
[50] G.R. Desiraju Angew. Chem. Int. Ed. 2007, 46, 8342 – 8356 
[51] W. C. McCrone, Physics and Chemistry of the Organic Solid State  Vol. 2 in Interscience, New York, 
p. 725, 1965. 
[52] J. Bernstein, Polymorphism in molecular crystals. Oxford University Press, Oxford, 2002, p.352 
[53] JD Dunitz, J Bernstein, Acc Chem Res, 1995, 28, 193-200. 
19 
 
[54] MH Klaproth, bergmannische J, 1798, I, 294-299. 
[55] E Mitscherlich 1823 Abhl Akad Berlin 43 
[56] Mitscherlich, E. Ann. Chim. Phys. 1822, 19, 350. 
[57] Mitscherlich, E. Ann. Chim. Phys. 1823, 24, 264. 
[58] Liebig, J.; Wöhler, F. Ann. Pharm. III 1832, 249, 514. 
[59] Hartley, H. Polymorphism: An Historical Account; Holywell Press: Oxford, U.K., 1902. 
[60] Deﬀet, L. Repertoire des Composes Editions Desoer: Liege, Belgium, 1942.Organiques 
Polymorphes 
[61] Groth, P. Chemische Krystallographie; Wilhelm Engelmann: Leipzig, Germany, 1906; Vol. I. 
[62] Groth, P. Chemische Krystallographie; Wilhelm Engelmann: Leipzig, Germany, 1908; Vol. II. 
[63] Groth, P. Chemische Krystallographie; Wilhelm Engelmann: Leipzig, Germany, 1910; Vol. III. 
[64] Groth, P. Chemische Krystallographie; Wilhelm Engelmann: Leipzig, Germany, 1917; Vol. IV. 
[65] Groth, P. Chemische Krystallographie; Wilhelm Engelmann: Leipzig, Germany, 1919; Vol. V. 
[66] NN Sirota, Cryst Res technol, 1982, 17, 661-691. 
[67] Nagase, H.; Ogawa, N.; Endo, T.; Shiro, M.; Ueda, H.; Sakurai, M. J. Phys. Chem. B 2008, 112, 
9105.  
[68] Eliel, E. L. Sterochemistry of Carbon Compounds; McGraw-Hill: New York, 1962. 
[69] Glusker, J. P.; Trueblood, K. N. Crystal Structure Analysis: A Primer; Oxford University Press: 
New York, 1985. 
[70] Dunitz, J. D. X-ray Analysis and the Structure of Organic Molecules; Cornell University Press: 
Ithaca, NY, 1979. 
[71] A.J. Cruz-Cabeza and J. Bernstein, Chem. Rev. 2014, 114, 2170−2191. 
[72] Vippagunta, S. R.; Brittain, H. G.; Grant, D. J. W. Adv. Drug Delivery Rev. 2001, 48, 3. 
20 
 
[73] Vistoli, G.; Pedretti, A.; Testa, B. Drug Discovery Today 2008, 13, 285. 
[74] S. Aitipamula, P. S. Chow and R. B. H. Tan, CrystEngComm, 2012, 14, 2381. 
[75] (a) M. A. Oliveira, M. L. Peterson and D. Klein, Cryst. Growth Des., 2008, 8, 4487; (b) M. 
Dabros, P. L. Emery and V.R. Thalladi, Angew. Chem., Int. Ed., 2007, 46, 4132. 
[76] (a) S. Cherukuvada and A. Nangia, CrystEngComm, 2012, 14, 2579; (b) N. R. Goud, K. Suresh, 
P. Sanphui and A. Nangia, Int. J. Pharm., 2012, 439, 63; (c) E. Lu, N. Rodríguez-Hornedo and R. 
Suryanarayanan, CrystEngComm, 2008, 10, 665;  (d) J. Lu, Y.-P. Li, J. Wang, Z. Li, S. Rohani and C.-
B. Ching, J. Cryst. Growth, 2011, 407, 63. 
[77] S. Cherukuvada and A. Nangia, Chem. Commun., 2014, 50, 906. 
[78] Etter MC, Reutzel SM, Choo CG, J. Am Chem Soc, 1993, 115, 4411-4412. 
[79] Zaworotko MJ, Crystal Growth & Design, 2007, 7, 4-9. 
[80] Hickey MB, Peterson ML, Scoppettuolo LA, Morisette SL, Vetter A, Guzman H, Remenar JF, 
Zhang Z, Tawa MD, Haley S, Zaworotko MJ, Almarsson O, Eur. J. Pharm Biopharm, 2007, 67, 112-
119. 
[81] Trask AV, Mol Pharm, 2007, 4, 301-309. 
[82] GRAS list, accessed 06 July 2012. 
[83] Brittain, H. G. (2011) Cocrystal Systems of Pharmaceutical Interest, Cryst. Growth Des., 2010, 
12, 1046-1054. 
[84] U.S. Department of Health and Human Services Food and Drug Administration Center for 
Drug Evaluation and Research (CDER) April 2013 CMC, Guidance for Industry Regulatory 
Classification of Pharmaceutical Co-Crystals 
[85] (a) Braga, D.; Grepioni, F.; Maini, L.; Prosperi, S.; Gobetto, R.; Chierotti, M. R. 
Chem.Commun. 2010, 46, 7715–7717.(b) D. Braga, F. Grepioni, G. I. Lampronti, L. Maini and A. 
Turrina, Cryst. Growth Des., 2011, 11, 5621–5627. (c) D. Braga, F. Grepioni, L. Maini, G. I. 
Lampronti, D. Capucci and C. Cuocci, CrystEngComm, 2012, 14, 3521–3527. (d) D. Braga, F. 
21 
 
Grepioni, L. Maini, D. Capucci, S. Nanna, J. Wouters, L. Aerts and L. Quéré, Chem. Commun., 
2012, 48, 8219–8221 (e) J. Wouters, F. Grepioni, D. Braga, R. M. Kaminski, S. Rome, L. Aerts and 
L. Quéré, CrystEngComm, 2013, 15, 8898–8902. (f) Fabrizia Grepioni, Johan Wouters, Dario 
Braga, Saverio Nanna, Baptiste Fours,Gérard Coquerel, Geraldine Longfils, Sandrine Rome, Luc 
Aerts and Luc Quéré, CrystEngComm, 2014,16, 5887–5896. 
[86] M.  D.  Eddleston,  S.  Sivachelvam   and W. Jones, CrystEngComm, 2013, 15, 175. 
[87] P. K. Thallapally, R. K. R. Jetti, A. K. Katz, H. L. Carrell, K. Singh, K. Lahiri, S. R. Kotha, R. Boese, 
G. R. Desiraju, Angew. Chem. 2004, 116, 1169 – 1175; Angew. Chem. Int. Ed. 2004, 43, 1149 – 
1155. 
[88] A. Delori, T. Friščić and W. Jones, CrystEngComm, 2012, 14, 2350. 
[89] A. V. Trask, W. D. S. Motherwell and W. Jones, Chem. Commun., 2004, 890. 
[90] O. M. Yaghi, M. O'Keeffe, N. W. Ockwig, H. K. Chae, M. Eddaoudi and J. Kim, Nature, 2003, 
423,  705. 
[91] J. Wang, L. Ding and C. Yang, CrystEngComm, 2007, 9, 591. 
[92] F. P. A. Fabbiani, D. R. Allan, W. I. F. David, S. A. Moggach, S. Parsons and C. R. Pulham, 
CrystEngComm, 2004, 6,  504. 
[93] Francesca P. A. Fabbiani and Colin R. Pulham, Chem. Soc. Rev., 2006, 35, 932–942. 
 
 
 
 
 
22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2 
Results and discussions 
23 
 
2 RESULTS AND DISCUSSIONS 
 
2.1 FOLIC ACID: AN INVESTIGATION OF SOLID-STATE PROPERTIES AND 
CRYSTAL FORMS 1 
 
2.1.1 Introduction 
 
Understanding structural diversity, in particular the formation and behavior of polymorphs, amorphous 
forms, solvates and co-crystals/salts, is critical for establishing uniqueness in a pharmaceutical patent 
or more in general in the pharmaceutical fields, as well as optimizing conditions for tablet compression 
and powder flow required for pharmaceutical compounding [1]. There is a strong interest in the 
application of crystal engineering approach to the pharmaceutical fields for the preparation of new 
formulation of active pharmaceutical ingredients (APIs), in particular co-crystals, that often show 
physical and chemical properties (solubility, intrinsic dissolution rate,  melting point, color, etc) different 
from those of their separate components. At the same time, the co-crystallization process does not 
affect the integrity of the molecular compounds. Another way to obtain useful change in the physical 
and chemical properties of new APIs is to obtain the amorphous solids. The importance of amorphous 
pharmaceutical compounds stems from useful properties such as higher stand solubility, higher 
dissolution rate and sometimes better compression characteristics than the corresponding crystals; to 
common occurrence, because the amorphous solids can be produced by standard pharmaceutical 
processes and are common form of certain materials (e.g., proteins, peptides, some sugars and 
polymers). Another important, but not useful, characteristic is that the amorphous solids are generally 
less physically and chemically stable than corresponding crystals [2].  
Recently a new class of co-crystals has been reported [3] that are called ICCs (Ionic CoCrystals) formed 
by an organic molecule and an inorganic salt [4], like an alkali or an alkali earth halide. ICCs can be 
obtained either by classic crystallization methods or by solid-state reactions between solid components 
(grinding and kneading [5]) with no or limited solvent involvement. Using the solvent free methods of 
synthesis, were obtained powders directly in solid state in agreement with green chemistry principles. 
                                                          
1 Saverio Nanna, Laura Chelazzi, Fabrizia Grepioni, Dario Braga (Manuscript in preparation) 
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In this work we have used salts of alkali and alkaline earth metals as co-formers. Using inorganic 
compounds in the formulation of API [4] makes possible to create a synergic effect between physical 
chemical properties of the single solid components (inorganic and organic matter). However, there is 
also another positive effect because of amorphous characteristics; therefore preparing “amorphous 
ICCs (Ionic CoCrystals)” with solvent free methods can be a useful tool to change in synergic way the 
physical properties of API. Summarizing there are many benefits using this approach on preparing 
eventually new formulation of active pharmaceutical ingredients:  
 Synthesis methods (solvent free); 
 Synergic effect between ionic compound and organic matter (API); 
 Properties of amorphous compound respect of crystalline powders. 
We studied Folic acid ((2S)-2-[(4-{[(2-amino-4-hydroxypteridin-6-
yl)methyl]amino}phenyl)formamido]pentanedioic acid (FA – Scheme 1), vitamin B9, that is the 
synthetic form of folate, which is a generic name to explain the different forms of vitamin 
pteroylglutamates (with various levels of reduction of the pteridine ring). This vitamin and its 
biologically active derivatives acts as coenzymes for synthesis and metabolism of many amino acids and 
nucleotides by single carbon transfer reactions. This is a very important process in metabolic pathways 
and a folic acid deficiency can lead to various illnesses. In detail, an insufficient level of vitamin B9 can 
lead to various diseases related to side effects such as neural tube defects (NTDs) [6], pregnancy 
complications, cancer, cardiovascular diseases [7]. Folic acid and its derivatives are also used in 
therapies for organic mental disturbance like senile and pre-senile primary degenerative dementia of 
Alzhheimer type [8]. Vitamin B9 is not produced by human body and therefore must be taken through 
the diet; folic acid that derives from the food is classified as food folate that exists predominantly in the 
polyglutamyl form containing up to seven glutamate residues [9]. In order to make it available to the 
intestinal absorption, a process that involves the hydrolysis of folate polyglutamates is necessary [10]. 
This process, together with other factors (for example low thermal stability of certain food folate), 
determines in general a lower bioavailability than synthetic folic acid fortified food [11]. The concept of 
bioavailability is therefore a very important key to human health and is used in special cases such as 
pregnancies, in which insufficient level of folic acid in the body is dangerous; it is therefore necessary 
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to take major amounts of folic acid [12]. The bioavailability of folate is defined as the ratio between the 
quantity of ingested folate and the one made available for metabolic processes. Folic acid and its 
derivatives, for which solution studies are known, are administered individually as salts (lithium, 
sodium, potassium, magnesium folate) [13].  
We focused on solid-state and dissolution properties of folic acid ionic co-crystals and salts, in order to 
further improve bioavailability and thermal stability of the native vitamin (synthetic folic acid); salts and 
co-crystals have been prepared via direct reaction   of folic acid in the solid-state, with no – or very 
limited amounts of –  solvent (grinding and kneading). The obtained compounds were analyzed through 
X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC) and thermogravimetric analysis 
(TGA) and variable-temperature X-ray powder diffraction (XRPD) to characterize thermal stability 
compared to native vitamin. Intrinsic dissolution rate (IDR) of each synthesis product was also 
measured.  
 
 
Scheme 1 – Folic acid molecule  
2.1.2 Experimental Details And Structure Determination From Xrpd Data 
 
All reagents and solvents were purchased from Sigma-Aldrich and used without further purification.  
Solid State Synthesis. Salts of folic acid with NaOH and Ca(OH)2 were obtained by manually kneading 
the two reagents in a ratio 1:2 in a agate mortar for 20 min with few drops of water; all reactions were 
quantitative. Salts and co-crystals of folic acid with LiOH and LiCl (with a molar ratio 1:2) were obtained 
by ball milling (using a Retsch MM200 grinder mill operated at a frequency of 20 Hz) and the reagents 
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were milled for 30 min with few drops of water, the reactions were quantitative. To obtain the co-
crystal of folic acid with Na2CO3, the two reagents were manually ground in a agate mortar without 
solvent with a molar ratio 1:2; the reaction was quantitative (Table 1). 
Table 1 - Reagents, synthesis methods and products obtained.  
 
 
 
 
 
 
 
TGA. TGA measurements were performed using a Perkin-Elmer TGA7 in the temperature ranges  40-
460 °C and 37-450 °C for the folic acid and the salts/co-crystal, respectively, under N2 gas flow, at a 
heating rate of 5°C min-1. 
DSC. DSC measurements were performed with a Perkin-Elmer Diamond. Samples (3-10 mg) were placed 
in open aluminium pans. Heating were carried out at 5°C min-1 for all the samples, in the temperature 
range 25-300°C. 
IDR. Dissolution rate in physiological solution at room temperature was measured for folic acid, the 
salts and the co-crystal. Measurements were carried out with a Varian Cary 50 Spectrophotometer 
equipped with a fiber optic dip probe. Four standard solutions in physiological solution (0.1 M NaCl) at 
concentrations 2.00, 4.00, 6.00, 8.00 mg∙L-1 were used to calculate a calibration curve for all the samples 
(correlation coefficient was 0.9988). Absorbance of the solutions was measured, the linear part of the 
spectrum between 0.1 and 0.6 min utilized, and its slope calculated, corresponding to the dissolution 
rate in time interval, expressed in Abs min-1. The Abs min-1 values were then interpolated in the 
calibration curve to find the dissolution rate of the analytes expressed as g∙sec-1.  
Reagents molar ratio solid-state technique Product 
FAH2·2H2O + LiCl               1:2 Ball milling FAH2·LiCl·nH2O 
FAH2·2H2O + Ca(OH)2             1:2 Kneading (H2O) CaFA·nH2O 
FAH2·2H2O + Na2CO3               1:1 Grinding CaFA·nH2O 
FAH2·2H2O + NaOH  1:2 Kneading (H2O) Na2FA·nH2O 
FAH2·2H2O + LiOH  1:2 Ball milling Li2FA·nH2O    
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XRPD Experiments.  For structure solution and refinement of folic acid and riboflavin, a X-ray powder 
diffractogram in the 2θ range 3-70° (step size 0.02°, time/step 15 s, VxA 40x40) were collected on D8 
Bruker diffractometer equipped with a primary Ge monochromator for Cu Kα1 and a Sol-X solid state 
detector in Debye-Scherrer geometry on a capillary with 0.05 mm of diameter.  
For phase identification purposes, X-ray powder diffractograms in the 2θ range 3-70° (step size 0.02°; 
time/step 20 s; 0.04° rad soller; VxA 40x40) were collected on a Panalytical X’Pert PRO automated 
diffractometer equipped with an X’Celerator detector in Bragg-Brentano geometry, using Cu K 
radiation without a monochromator.  
Variable Temperature X-ray Diffraction. X ray powder diffractograms in the 2 range 3-70° were 
collected on a Panalytical X’Pert PRO automated diffractometer equipped with an X’Celerator detector 
and an Anton Paar TTK 450 system for measurements at controlled temperature. The data were 
collected in open air in Bragg-Brentano geometry using a Cu K radiation without a monochromator.  
Structure Determination 
 Folic acid·2H2O. Powder diffraction data were analyzed with the software Highscore plus. 15 peaks 
were chosen in the 2θ range 3-40°, and unit cell parameters were found thanks to the algorithm DICVOL 
[14]. For Folic acid was found a monoclinic unit cell with a volume of 2033.3(4) Å3. In the asymmetric 
unit were found the presence of one molecule of folic acid and two molecules of water. Space group 
determination with Highscore plus resulted in space group P212121, with Z = 4, Z’ = 1. The structure was 
solved by simulated annealing using all independent ions and molecules. Simulated annealing, that runs 
with structure fragments, was performed with EXPO2010, the updated version of EXPO2009 [15], using 
one folic acid molecule and two independent water molecules. Ten runs for simulated annealing trial 
were set, and a cooling rate (defined as the ratio Tn/Tn-1) of 0.95 was used. Best solutions were chosen 
for Rietveld refinements, which was performed with the software TOPAS [16]. A shifted Chebyshev 
function with 16 parameters and a Pseudo-Voigt function were used to fit background and peak shape, 
respectively. Soft constraints were applied for all bond distances and angles of the folic acid molecule, 
and a planar group restraint was applied to the aromatic ring. An overall thermal parameter was 
adopted for all atoms of the folic acid molecules. All the hydrogen atoms were fixed in calculated 
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positions. Refinement converged with 2 = 1.28 and Rwp = 9.68 (Table 2). Figure 1 shows the 
experimental, calculated and difference diffraction patterns.  
 
Figure 1 - Experimental (black curve), calculated (red curve), and difference (grey curve) powder pattern for folic 
acid · 2H2O. Peak positions are marked in blue. 
Determination of the unit cell parameters (Pawley refinement) of the folic acid (anhydrous form) at 
high temperature. Powder diffraction data were analyzed with the software Highscore plus. 15 peaks 
were chosen in the 2θ range 3-40°, and unit cell parameters were found thanks to the algorithm 
DICVOL. For the anhydrous form of the Folic acid was found a monoclinic unit cell with a volume of  
3170.4(7) Å3. The volume is consistent with the presence of three folic acid molecules in the asymmetric 
unit. The Pawley fit was performed with the software TOPAS. A shifted   Chebyshev with 8 coefficients 
and a pseudo-Voigt function were used to fit background and peak shape, respectively. Refinement 
converged with 2 = 1.40 and Rwp = 3.23 (Table 2). Figure 2 shows the experimental, calculated and 
difference diffraction patterns.  
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Figure 2 – Experimental (blue curve), calculated (red curve), and difference (gray curve) powder pattern for HT 
folic acid. Peak positions are marked in blue. 
 
Table 2 – Details of data collection and structure refinement of folic acid, and Pawley fit of the anhydrous form.   
 
Folic acid · 2H2O 
Structure refinement 
Folic acid HT (anhydrous form) 
Pawley fit 
Chemical formula C19 H23 N7 O8 C19 H19 N7 O6 
M r 477.40 336.25 
temp/K 293 293 
wavelength (Å) 1.54056 1.54056 
crystal system orthorhombic monoclinic 
space group P212121 P 21 
a/Å 8.6163(9) 28.812(3) 
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[N.B.: Science data: RT, single crystal;  R1 (all data) = 0.184, R1 (observed) 0.146] 
2.1.3 Results And Discussion 
 
The structure solution of Folic acid 
The structure of Folic acid was solved in 1980 [17] by single crystal X-ray diffraction with an 
orthorhombic unit cell and R value based on the observed data of 0.146. The authors of this work give 
a description of the structure and a figure without the atomic coordinates. With the intent of study the 
relationships between the structure and the properties of folic acid and its ionic co-crystals and salts, 
we managed to obtain the atomic coordinates and a more detailed structure. Due to the impossibility 
to obtain single crystals of a suitable dimension to study by single crystal X-ray diffraction, we decided 
to try to solve the structure with X-ray powder diffraction. We obtained two different structure that 
differ only for the conformation of the glutamic moiety and after the refinement it was clear that one 
structure has a better result than the other and the result was in disagreement with that obtained with 
the single-crystal X-ray diffraction. Single crystal X-ray diffraction is surely the principle techniques to 
obtain reliable structural data, but sometimes a single crystal is not representative of the bulk of 
products and the study of the bulk is only possible using X-ray powder diffraction. The use and the 
synergy of different techniques can be a useful tool to solve complex problem and  
b/Å 32.428(4) 4.424(9) 
c/Å 7.2771(5) 26.37(2) 
β/deg - 109.38(2) 
V/Å3 2033.3(4) 3170.4(7) 
Z 4 6 
Rwp 9.68 3.23 
2 1.28 1.40 
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Folic acid·2H2O. Figure 4 shows a schematic representation of the structure of Folic Acid (FA) · 2H2O. 
The crystal structure was described in the literature [17] in 1980, but only cell parameters were 
deposited in the Cambridge Structural Database (refcode FOLCAH).  As described in Mastropaolo et al., 
each folic acid is hydrogen-bonded to two other folic acid and two water molecule .  
 
 
 
 
 
 
Figure 3. Schematic representation of Folic acid structure hydrogen-bonded to two water molecule. Colour 
codes: orange, carbon; red, folic acid oxygen; blue, water oxygen; green, nitrogen; grey, hydrogen (in the scheme 
some hydrogen atoms involved in inter and intra molecular interactions are reported). 
The pteridine ring and the glutamic acid residue of each folic acid molecule are linked to the glutamic 
acid residue and the pteridine ring of the two adjacent folic acid molecules respectively. The p-
aminobenzoyl group of one molecule of folic acid is almost below the pteridine ring of the symmetry 
related folic acid molecule. Zig-zag chains of folic acid are linked together by a bridged water along the 
b axes and these chains form a 3D network stabilized by hydrogen bond interaction (Figure 4).  
    
(a) (view down the c-axis)  
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(b) (view down the a-axis) 
Figure 4. Packing pattern for folic acid with two water molecules - (a) view down the c-axis – (b) view down the 
a-axis. Colour codes: orange, carbon; red, folic acid oxygen; blue, water oxygen; green, nitrogen; grey, hydrogen. 
Variable temperature X-ray powder diffraction experiments of the dihydrate form has been carried out 
to verify the crystal structure stability after the dehydration process (Figure 5). The loss of water and 
the subsequent solid-solid transition to the anhydrous phase has been observed at 150°C.  After cooling 
at 25°C, the restoration to the hydrate phase occurred in few minutes; the crystallinity of the folic acid 
increases with increasing of time (Figure 5). So far, we have not managed to determine the structure of 
the HT form (anhydrous form) due to the low quality of the diffraction pattern. 
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Figure 5.  XRPD patterns for folic acid at room temperature (bottom curve), at 150°C (red curve) and at room 
temperature after cooling (top curve). 
Our aim was to obtain folic acid salts or co-crystals using inorganic salts as coformers with solvent free 
methods. Synthesis products were analyzed by XRPD and the diffraction powder patterns were 
characteristic of an amorphous phase. In some cases, diffraction pattern shows the presence of the 
inorganic salt due to the different stoichiometric ratio and the presence of the reagents used for the 
synthesis due to the incomplete reaction between them (Figure 6). 
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Figure 6. XRPD patterns of folic acid and its salts and co-crystals. 
Due to the amorphous patterns of synthesis products, the samples have been characterized by 
TGA/DSC and IDR in order to verify the complete reaction between reagents, and to compare thermal 
stability and dissolution rate respect to the native vitamin. Comparing TGA experiments of our products 
with commercial folic acid, has been observed an improvement of thermal stability. This phenomenon 
suggests the presence of salts and co-crystals due to the occurred complete reaction. In figure 7 is 
shown the comparison between the TGA experiment of native folic acid [18] and FA·LiOH; in the 
FA·LiOH plot there is no peaks related to folic acid and the decomposition of salt occurs at about 350 
°C (100°C more stable than pure folic acid). However there are no peaks related to folic acid for none 
of the samples studied because only traces of the two components have not reacted. The only sign of 
the presence of small quantity of FA is a small change in the slope at about 250°C corresponding to the 
temperature of melting and degradation of FA (see SI – figure S1). For the inorganic salts, the m.p. 
temperature occurs at higher degree respect to the temperature analysis.  
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Figure 7. Thermogravimetric analysis (TGA) of folic acid (a) and FA·LiOH (b) 
As stated in the introduction, new formulations synthesized directly in the solid state, has been tested 
in order to verify their physical properties in solution, in particular the intrinsic dissolution rate; the 
possibility to increase this property respect to the native vitamin could be a very interesting aspect for 
the possible application in the pharmaceutical field.  
IDR measurements show an increase of IDR of salts and co-crystals up to eight times value of pure folic 
acid (see Table 3 and Figure 8).  
Loss of 
2∙H2O 
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Table 3 - IDR measurements 
 
 
 
 
 
 
 
 
 
Figure 8. Intrinsic dissolution rate (IDR) measurements of Folic acid and its salts and co-crystals. 
 
 
 
 G/sec 
FA 1.26796E-05 
FA·Na2CO3 3.92932E-05 
FA·LiCl 1.59004E-05 
FA·LiOH 8.62485E-05 
FA·NaOH 4.96336E-05 
FA·Ca(OH)2 1.67479E-05 
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2.1.4 Conclusions 
 
In this paper, we have reported the structure of folic acid solved by XRPD and the discover of the high 
temperature phase. The structure solution by X-ray powder diffraction data is a useful tool in case of 
Salts and co-crystals of folic acid with inorganic salts were synthesized by solvent free methods and 
characterized by TGA/DSC and were tested their intrinsic dissolution rate. This study highlights the 
importance of using different routes of preparation to obtain new APIs. In particular, the solid-solid 
reaction can be used to produce new forms with different physical chemical parameters. This aspect 
together with the possibility to obtain stable amorphous phase over time, without changing the 
chemical entity, could be an interesting way to obtain new useful results in the pharmaceutical field.  
SUPPORTING INFORMATION 
Below are reported the Thermogravimetric analysis (TGA) of the reaction product of folic acid with LiCl, 
Na2CO3 , NaOH and Ca(OH)2 respectively. 
 
(a) 
38 
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(d) 
Figure S1. Thermogravimetric analysis (TGA) of (a) FA·LiCl, (b) FA·Na2CO3 , (c) FA·NaOH and (d) FA·Ca(OH)2. 
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2.2 FOLIC ACID REVISITED: A SYNERGIC COMPUTATIONAL, SPECTROSCOPIC 
AND STRUCTURAL APPROACH IN THE SOLID-STATE. 2 
 
2.2.1 Introduction 
 
Folic acid ((2S)-2-[(4-{[(2-amino-4-hydroxypteridin-6-yl)methyl]amino}phenyl)formamido]pentanedioic 
acid (FA – Scheme 1) is the vitamin B9, that is the synthetic form of folate, which is a generic name to 
explain the different forms of vitamin pteroylglutamates (with various levels of reduction of the 
pteridine ring). This vitamin and its biologically active derivatives act as coenzymes for synthesis and 
metabolism of many amino acids and nucleotides by single carbon transfer reactions. This is a very 
important process in metabolic pathways and a folic acid deficiency can lead to various illnesses. In 
detail, an insufficient level of vitamin B9 can lead to various diseases related to side effects such as 
neural tube defects (NTDs) [1], pregnancy complications, cancer, cardiovascular diseases [2]. Vitamin B9 
is not produced by human body and therefore must be taken through the diet in form of tablets. The 
upside of understanding the solid state of molecules is reflected into the deep comprehension of the 
relationships between structure and properties. The administration of folic acid could be a blind test 
without the acknowledgement of its intrinsic properties in solid state. 
Scheme 1. Folic acid molecule.  
 
                                                          
2  Saverio Nanna, Laura Chelazzi, Fabrizia Grepioni, Dario Braga, Lorenzo Maschio, Paola Taddei (Manuscript in 
preparation) 
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2.2.2 Results And Discussion 
 
The structure of Folic acid was solved in 1980 [3] by single crystal X-ray diffraction with an orthorhombic 
unit cell and R value based on the observed data of 0.146. The structure was described only by a stereo-
view figure and no atomic coordinates were provided. With the intent of studying the relationships 
between the structure and the properties of folic acid, we managed to obtain the atomic coordinates 
and a more detailed structure. We were not able to obtain single crystals of a suitable dimension for a 
single crystal X-ray diffraction study, and for this reason we managed to solve the structure with X-ray 
powder diffraction. Folic acid is not a simple molecule to be solved by powder data due to the presence 
of several degrees of freedom in the glutamic moiety. We obtained two different solutions that differ 
just for the conformation of the glutamic moiety; one conformation that reflects the structure described 
in literature (FOL2, Figure 1, top), seems to be less accurate than the other conformation calculated 
(FOL1,Figure 1, bottom).    
 
 
 
 
 
 
Figure 1. Different conformation of the glutamic moiety of the two solutions.  
Powder diffraction data were analyzed with the software Highscore plus. 15 peaks were chosen in the 
2θ range 3-40°, and unit cell parameters were found thanks to the algorithm DICVOL [4]. For Folic acid 
was found a monoclinic unit cell with a volume of 2033.3(4) Å3. In the asymmetric unit the presence of 
one molecule of folic acid and two molecules of water was found. Space group determination with 
Highscore plus resulted in space group P212121, with Z = 4, Z’ = 1. The structure was solved by simulated 
annealing using all independent ions and molecules. Simulated annealing, that runs with structure 
fragments, was performed with EXPO2010, the updated version of EXPO2009 [5], using one folic acid 
FOL 1 
FOL 2 
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molecule and two independent water molecules. Ten runs for simulated annealing trial were set, and a 
cooling rate (defined as the ratio Tn/Tn-1) of 0.95 was used. Best solutions were chosen for Rietveld 
refinements, which was performed with the software TOPAS [6]. A shifted Chebyshev function with 16 
parameters and a Pseudo-Voigt function were used to fit background and peak shape, respectively. Soft 
constraints were applied for all bond distances and angles of the folic acid molecule, and a planar group 
restraint was applied to the aromatic ring. An overall thermal parameter was adopted for all atoms of 
the folic acid molecules. All the hydrogen atoms were fixed in calculated positions. Refinement 
converged with χ2 = 1.28 and Rwp = 9.68 . Figure 2 shows the experimental, calculated and difference 
diffraction patterns.  
 
 
Figure 2. Experimental (black curve), calculated (red curve), and difference (grey curve) powder pattern for folic 
acid∙2H2O. Peak positions are marked in blue.  
With flexible molecules, X-ray powder diffraction could be a useful tool to obtain the crystal structure 
but there is need of a synergic contribution of other complementary techniques. The characterization 
of the samples has been achieved through combination of ab initio calculations and Raman 
spectroscopy. 
DFT calculation have been carried out using the CRYSTAL ab initio program[7], that uses a gaussian basis 
set. The method adopted for all calculations was a B3LYP hybrid functional, that has proven to provide 
remarkably good results in the evaluation of the vibrational properties of several crystalline compounds 
[8], including such complex structures as Metal-Organic Frameworks[9,10]. A 6-31G** basis was used 
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for geometry optimizations and frequency calculations, while a cc-pVTZ basis set was also adopted for 
the evaluation of relative stability (see below). Empirical D2[11] dispersion correction has been also 
included as reparametrized for solids by Civalleri et al.[12] The two structures have been fully optimized 
(unit cell and atomic positions), with the resulting lattice parameters (in Angstrom): 
 a b c Vol 
FOL1 8.5019 31.1668 7.5000 1987.32 
FOL2 8.7628 34.2373 6.7595 2027.95 
Exp. FOL1 8.6163 32.4284 7.2771 2033.34 
Exp. FOL2 8.6168 32.4337 7.2788 2034.25 
 
It can be noticed that the FOL1 structure results in a more compressed volume with respect to the 
experiment. This is most likely to be ascribed to basis set incompleteness effects that are accounted for 
in the Raman spectrum calculation (vide infra) by suitable shifting of the computed wavenumbers. The 
volume of FOL2 structure is more similar to the experimental one but the lattice is considerably 
distorted, with a very compressed c parameter and overestimated a and b lattice components. 
The relative stabilities of the two crystalline phases have been computed by standard counterpoise 
methods to account for Basis Set Superposition Error (BSSE) effects. As shown in earlier works[13], the 
6-31G**/B3LYP level is often sufficient for a good estimate of formation energies of crystals. 
In table 1 we report, for the two adopted basis sets:  
1) the relative stability (per formula unit) between the two crystalline structures, evaluated as the 
difference between the total crystalline energy divided by the number of formula units in the cell. 
∆𝐸𝑐𝑟𝑦 = (𝐸𝑐𝑟𝑦
𝑓𝑜𝑙1 −  𝐸𝑐𝑟𝑦
𝑓𝑜𝑙2)/4 
2) the conformational energy, evaluated as the difference between the total energy of the Folic acid 
molecule, in the conformation adopted in the two different crystalline structures 
∆𝐸𝑐𝑜𝑛𝑓 = 𝐸𝑚𝑜𝑙
𝑓𝑜𝑙1 − 𝐸𝑚𝑜𝑙
𝑓𝑜𝑙2
 
3) Finally, the zero point vibrational contribution (per formula unit) has been evaluated (only at the 6-
31G** level) thanks to the availability of the computed full vibrational spectrum of the two crystals: 
∆𝐸𝑣𝑖𝑏 = (𝐸𝑣𝑖𝑏
𝑓𝑜𝑙1 −  𝐸𝑣𝑖𝑏
𝑓𝑜𝑙2)/4 
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Table 1. Computed relative energies (values in kJ/mol) of the two crystalline phases of Folic acid, as obtained with 
6-31G** and cc-pVTZ basis sets using the B3LYP Hamiltonian. See text for the definition of energy contributions 
 
 
 
 
 
As a side note, we recall that use of augmented basis sets, such as cc-pVTZ, is not possible in crystalline 
systems since diffuse functions lead to linear dependencies and numerical issues in the calculation. 
The Raman spectra have been calculated thanks to an entirely analytical method for the evaluation of 
transition intensities [14,15], that has been recently implemented in the CRYSTAL code. [7] This method, 
that is unique among solid state quantum chemistry programs, uses a Coupled-Perturbed Hartee-
Fock/Kohn Sham (CPHF/KS) approach to evaluate the perturbation in the density due to the electric 
field, and combines it with analytical first order gradients to obtain the needed third-order derivatives. 
The derived equations, do not need gradients of the electronic density, thus making the computational 
effort optimal.  
Structure FOL1 was found to be substantially more stable than the FOL2, by an amount of 17.3 kJ/mol 
per unit formula. This, despite the fact that the molecule itself is in a configuration that is, according to 
our calculations, less stable by about 10 kJ/mol. The latter result can be of interest in understanding the 
kinetics of the crystal formation. 
Vibrational Raman spectroscopy represents a powerful tool to investigate and identify substances 
because it provides fingerprint spectra that are unique to each specific compound and its 
molecular packing. No Raman studies and vibrational assignments for solid folic acid have been 
reported in the literature. On the other hand, surface-Enhanced Raman spectroscopic (SERS) 
studies in aqueous solutions have been aimed at setting up analytical methods to selectively detect 
folic acid in water and biological samples [16]; moreover, resonance Raman studies in aqueous 
solutions have allowed to clarify the binding of folate and methotrexate to dihydrofolate 
reductases [17-19]. Due to the lack of solid-state Raman studies on folic acid, the Raman spectrum 
 6-31G** cc-pVTZ 
∆𝐸𝑐𝑟𝑦 -14.06 -16.56 
∆𝐸𝑐𝑜𝑛𝑓 17.69 10.03 
∆𝐸𝑣𝑖𝑏 -0.72  
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of this compound was recorded (FT-Raman, λexc = 1064 nm, laser power at the sample 40 mW) 
and was compared with the spectra obtained for FOL1 and FOL2 by theoretical calculations. In 
figure 3, the full spectrum in the range 1800-50 cm-1 is reported, as measured and computed for the 
two structures and the band wavenumber values and assignments were compared as well (Table 2). 
Intensity of the peaks is in arbitrary units, and the computational spectra have been renormalized so 
that the tallest peak of the blue spectrum (80 cm-1) has the same height as the corresponding 
experimental one. Computed frequencies have been downscaled, as customary since long in ab initio 
vibrational frequency calculations,[20] by a factor 0.985, and upshifted by 45 cm-1 in order to 
compensate for underestimation of lattice volume, as discussed above. The experimental Raman 
spectrum was recorded on a Bruker MultiRam FT-Raman spectrometer equipped with a cooled Ge-
diode detector. The excitation source was a Nd3+-YAG laser (1064 nm) in the backscattering (180°) 
configuration. The focused laser beam diameter was about 100 µm and the spectral resolution 4 cm-1. 
The spectrum was recorded with a laser power at the sample of about 40 mW. 
 
Table 2. Experimental and calculated wavenumber values and assignments of the most significant Raman bands 
Assignments based 
on solid model 
compounds 
Assignments 
based on folic acid 
and model 
compounds in 
solution 
Experimental 
wavenumber value 
(cm-1) 
Calculated 
wavenumber value 
(cm-1) and 
assignment 
FOL1 
Calculated 
wavenumber value 
(cm-1) and 
assignment 
FOL2 
C=O stretching Glu 
[21]  
 1710 1705 C=O stretching 
Glu 
 
1747 C=O stretching 
Glu 
C=O stretching Glu 
[21] 
Pter protonated 
N5=C6 
stretching[19]; C=O 
stretching PABA-
Glu[25]  
 
1664 1672 C=O stretching 
Pter ring 
 
1675 C=O stretching 
Pter ring 
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NH2 scissoring  
biopterin [23] 
Pter unprotonated 
N5=C6 
stretching[13]; 
Amide I (C=O 
stretching) 
tetrahydrofolate[25
] 
1637 1631 NH2 scissoring 
+ H2O scissoring  
 
1642 (very weak) 
NH2 scissoring + 
N1=C2 stretching 
 
CC stretching 
PABA[15];  
0+21 C=C 
stretching Pter 
modes[24] 
PABA[17], benzoyl 
ring mode of 1,4-
disubstituted 
benzene[18]; Pter in 
methotrexate[17,26
]; 8a PABA-Glu[25] 
1607 1601 C=C stretching 
benzene ring + H2O 
and NH2 scissoring  
1595 C=C stretching 
benzene ring + NH2 
scissoring 
 
1608 C=C stretching 
benzene ring + H2O 
scissoring  
1603 H2O scissoring 
+ NH2 scissoring 
5 Pter mode [24]; 
pyrimidine ring 
quadrant stretching 
biopterin [23] 
 
PABA [17]; 8b 
PABA-Glu [25] 
1570 1568 C=N Pter ring 
stretching 
 
1573 NH2 scissoring 
 
CH2 wagging 
Glu[21]; 11 and 
12 Pter modes[24]; 
C-H in plane 
bending 
biopterin[23] 
 
PABA[17]; Pter ring 
vibration[26]; Pter 
ring stretching C-N; 
Pter in 
methotrexate[17,26
] 
1357 
 
1351 Pter C=N 
stretching + CH2 
wagging, Pter ring 
breathing 
 
 
 
CC and C-OH 
stretching 
PABA[22]; CH2 
twisting Glu[21]; 
13 Pter mode[24]; 
C-H out-of-plane 
PABA[17]; Amide III 
PABA-Glu[25]; 
Amide III folate[25] 
1291 1290 C-H wagging 
mainly Glu 
 
1282 C4a=C8a 
stretching 
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bending 
biopterin[23] 
 Pter in 
methotrexate[17] 
 
1251 1258 N-H wagging 1230 N-H and C-H 
wagging 
CH in plane bending 
PABA[22]; 15 and 
22+23 Pter 
modes[24] 
C9-N10 
stretching[18]; 9a 
PABA-Glu[25] 
1193-1179 1193-1178 CH + CH2 
+ NH wagging  
 
1181 CH2 wagging 
  153 162 Pter flexural 
modes 
143 Pter torsional 
modes 
 
178 Pter flexural 
modes 
140 Pter torsional 
modes 
 
  119 120 H2O 
translational mode 
127 H2O 
translational mode 
110 benzene ring 
rotation 
  82 80 torsional modes 
Glu 
 
85 (weak) torsional 
modes (C6-C9) 
PABA= p-aminobenzoic acid; Glu = glutamic acid; Pter = pteridine; PABA-Glu= p-aminobenzoylglutamate 
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Figure 3. Experimental and calculated Raman spectra, FOL1 (blue trace) and FOL2 (red trace). 
The spectrum calculated for FOL1 (blue trace) showed a better agreement with the experimental data 
(black trace), especially in the low-wavenumber region, where lattice vibrations fall, and in the 1750-
1100 cm-1 range. The assignments obtained from theoretical calculations showed a good agreement 
with those reported in the literature for solid model compounds[19-24] as well as for folate and model 
compounds in solution [17-19,25,26] (see Table 2).  The obtained results represent a strong evidence 
supporting the FOL1 newly proposed crystal structure. 
 
2.2.3 Conclusions 
 
It was pointed out how the synergic combination of different techniques at the solid state could be a 
power-full tool to solve complicated structural problems. The structure of folic acid was solved with X-
ray powder diffraction and ab initio calculations reporting for the first time the Raman spectra with 
peaks assignment too. 
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2.3 IONIC CO-CRYSTALS OF PIRACETAM: FROM SOLID TO SOLUTION 3  
 
2.3.1 Introduction 
 
Ionic co-crystals (ICCs) [1] represent a new class of co-crystals of pharmaceutical interest, 
constituted by an organic molecule and an inorganic salt, like an alkali or alkaline earth halide. These 
compounds are characterized by the fact that the organic molecule, solid as a pure compound at 
ambient conditions, acts as a sort of solvating molecule toward the ions, competing with water 
molecules for ions coordination.[2] Here we report the study of the stability, at the equilibrium, in 
organic and aqueous solution of ICCs composed by piracetam with LiCl, LiBr, CaCl2 and SrCl2, 
respectively. Piracetam (PIR), 3a 2-oxo-1-pyrrolidine acetamide, is currently approved in over 100 
countries for use in adults and the elderly for the treatment of vertigo and events associated with 
ageing. It belongs to a family of cognition enhancing medicines called nootropics, and was 
synthesized in 1964 by scientists at UCB. The inorganic salts used, on the other hand, have been 
chosen for their nontoxicity and potential applications in the pharmaceutical field. These systems 
were synthesized through crystallization from solution or by solid-state reactions between solid 
components  with no (grinding) or limited (kneading) solvent addition. Their crystalline structures, 
solid state properties (thermal stability) as well as the intrinsic dissolution rate (IDR) studies have 
been published by the Crystal Engineering Group at Unibo.[2b,d]   No studies in solution at 
equilibrium on ionic co-crystals are known from the literature. Ionic co-crystals of Piracetam with 
LiCl have been studied in solution through kinetic measurements of dissolution in physiological 
solution [2d]; kinetic and equilibrium solubility measurements represent two complementary 
resources, useful to classify a drug and a corresponding co-crystal from a solubility point of view. 
Going beyond this aspect, a synergic approach between kinetic and equilibrium measurements 
yields either a deep knowledge of the system, as a learning model, and the opportunity to approach 
other scenarios that would otherwise not be accessible. Here we report solubility and stability in 
solution studies, which exploit the methods for equilibrium measurements of co-crystal solubility, 
developed by Rodrigruez et al. [1] Solubility as well as permeability are a critical point in the 
                                                          
3 Saverio Nanna, Fabrizia Grepioni, Rodriguez Nair-Hornedo (Manuscript in preparation) 
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pharmaceutical development of a drug, as they are reflected on the oral absorption according to 
the biopharmaceutics classification system (BCS). Piracetam belongs to class I of BCS, i.e. it is a drug 
soluble as well as permeable. The aim of this study is (1) to investigate the co-crystal solubility in 
order to figure out the solution chemistry and the behaviour of ICCs related to the properties of the 
pure components, (2) to study the solubilizing effect of salts on piracetam due to the solute-solute 
and solvent-solute interactions, and (3) to explore how the interactions in solution effect the solid 
state properties in terms of hygroscopicity. 
 
 
 
 
Scheme 1 Piracetam molecule. 
2.3.2 Experimental Section 
 
Materials.  
Piracetam (PIR) and all the other reagents were purchased from Sigma-Aldrich and used without 
further purification.   
Preparation of Ionic Co-Crystals.  
Grinding experiments in an agate mortar for 20 min were performed on commercial piracetam 
(commercial Form III) (1,1 g, 7,5 mmol - see SI – figures S1-S5) with LiCl (0,3 g, 7,5 mmol) and LiBr 
(0,7 g, 7,5 mmol) respectively. Kneading (with a catalytic amount of water) experiments of 
commercial piracetam (0,8 g , 5,4 mmol) with CaCl2 (0,3 g, 2,7 mmol) and SrCl2 ∙ 6(H2O) (0,7 g, 2,7 
mmol) were also carried out (see Table 1). ICCs were produced also from solution adding an excess 
of PIR to a nearly saturated solution of co-former (inorganic salt).  
Solubility of ICCs and ICCs components.  
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The solubility of PIR in water and in ethanol at the equilibrium was determined at 25 ± 0.5 °C. The 
solubility studies of the ICCs in water and ethanol were performed carrying out, either slurry 
experiments of ICC (method 1), either slurry experiments using the eutectic approach (method 2). 
[1] The experiments, relative to the method 2, were conducted by adding an excess of ICC 
[PIR∙LiCl∙2(H2O) (1), PIR∙LiBr∙2(H2O) (2), PIR2∙CaCl2∙2(H2O) (3) respectively] and PIR at the same time 
in 8 mL glass vials. The suspensions were magnetically stirred and withdrawn each 24h; the solid 
phase, filtered and dried, was characterized by XRPD and DSC. Once solid phase is stable for 48 h, 
the concentrations were measured by UV-spectrophotometer and ICP-OES as described below.  
UV-spectrophotometer.  
[PIR] was measured by Agilent 8453 UV- Visible spectrophotometer. 
The Agilent 8453 spectrophotometer is a single-beam, microprocessor-controlled, UV-visible 
spectrophotometer with collimating optics. Performance specifications - Wavelength range 190–
1100 nm - Slit width 1 nm - Resolution > 1.6 - Wavelength accuracy < ± 0.5 nm - Wavelength 
reproducibility < ± 0.02 nm. 
ICP-OES.  
The concentration of inorganic salts was monitored through ICP-OES.  
Spectrometer specifications. “The OPTIMA 2000 ICP-OES uses a unique double-monochromator 
optical system. The first, or preselection monochromator (focal length of 0.3 meter and a Stigmatic 
Littrow configuration), selects a small portion of the spectrum around the analytical line of 
interest.The second, the Echelle-based (focal length of 0.3 meter and a Stigmatic Littrow 
configuration) high dispersion monochromator, disperses the narrow wavelength range onto the 
DBI-CCD. The spectral range is 160–900 nm. The slew rate is less than 3 seconds to cover the spectral 
range, and the measured resolution is <0.009 nm @ 200 nm. The prism and Echelle grating are 
rotated less than ± 2 degrees to access any wavelength, dramatically improving analytical speed. 
The UV-sensitive, dual backside-illuminated CCD detector is cooled directly using a single-stage 
integrated Peltier cooler operated at approximately -8°C.The detector housing is hermetically sealed 
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and is filled with dry nitrogen to eliminate condensation. The detector has two photosensitive 
segments containing 176 by 128 pixels. 
ICP system specifications. The OPTIMA 2000 ICP-OES features a 40-MHz, free-running, solid-state 
(no power amplifier tube needed) RF generator, adjustable from 750 to 1500 watts, in 1-watt 
increments. Water recirculating cooling system works at 4 L/min flow capacity at 310 to 550 kPa 
and a temperature between 15°C and 25°C. 
X-ray powder diffraction  
X-ray powder diffraction diffractograms of solid phases were collected with a benchtop Rigaku 
Miniflex X-ray diffractometer (Rigaku, Danverse, MA) using Cu Kα radiation (λ= 1.54Å), a tube 
voltage if 30kV, and a tube current of 15 mA. Data were collected from 5 to 40° at a continuous scan 
rate of 2.5°/min.  
Differential scanning calorimetry (DSC).  
Solid phases collected from the slurry studies were dried and analyzed by differential scanning 
calorimetry (DSC) using a TA instrument (Newark, DE) 2910MDSC system equipped with a 
refrigerated cooling unit. DSC experiments were performed by heating the samples at a rate of 5-
10 °C/min  under a continuously purged dry nitrogen atmosphere (flow rate 50 mL/min). Samples 
were scanned over the range 30-250°C. Standard aluminum sample pans were used for all 
measurements.  
2.3.3 Results And Discussion 
 
The first step was to assess the solubility of PIR in water at 25°C through UV-spectroscopy; solubility 
in ethanol at RT (room temperature) is known from literature [3]. Slurry experiments in water at 25 
± 0.1°C were carried out (see Table 1).    
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Table 1. Solubility at 25±0.1°C of piracetam (Form III – commercial form) 
 
Solvent [PIR] (M) (mean ± range) 
H2O 3,7 x 100 ± 3 x 10-3  
  
Ethanol 2,1 x 10-1 ± 2 x 10-4 
 
 
 
 
 
(a)  
 
(b) 
Scheme 2. Chemical equilibria in solution (a) and general equation to calculate the co-crystal solubility (b) 
[1b] 
 
Ionic Co-Crystals -- PIR∙LiCl∙2(H2O) (1)  PIR∙LiBr∙2(H2O) (2) 
Solubility in water 
Method 1. Solubility in water was investigated preparing suspensions of Ionic co-crystals (ICC), 
stirred for one week; the solid phase of each one was checked every 24 h and considered at the 
equilibrium with aqueous solution, once the solid phase was stable for at least 72 h. The 
characterization of the solid phase, performed with XRPD and DSC measurements, showed no 
transition of the ICCs to the drug (PIR), suggesting that all ICCs under investigation are less soluble 
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than the piracetam (see SI – figures S6,S7,S13,S14). The concentration values, listed in table 2, 
showed a spread between [PIR] and [salts], especially for 2; the fact that the stoichiometric ratio in 
solid is not reflected in solution is due to the hygroscopicity of the alkali and alkaline earth metals 
halide.  
Method 2.The weighing process of the salts, stored in presence of P2O5, is crucial; to overcome the 
problems relative to the hygroscopicity of the salts, the eutectic approach was applied. This method 
developed by Rodriguez et al. [1], consists on reaching the eutectic point, in which both solid phases 
are in equilibrium with solution (ternary system); this is an invariant point with pH and temperature 
constant[1,4]. It should not to be confused with the original term “eutectic”, which is used to 
describe, the transformation on cooling from an homogeneous liquid to a two-phases solid. The 
eutectic approach is useful to determine readily the concentration at the equilibrium of co-crystal 
components, when the solubility of co-crystal is higher than that of the pure drug. In our case (ICCs 
are less soluble than the piracetam), this method is still useful as we can calculate, accurately, the 
solubility of the ICCs regardless of drug:salt ratio in solution. There are various methods to reach 
the eutectic point [1b]; we adopted that in which the experiments were conducted by adding an 
excess of ICC and PIR at the same time in 8 mL glass vials.  
The eutectic concentrations (Ceu), corresponding at the eutectic point, were confirmed by XRPD and 
DSC analysis of the solid state (see SI – figure S8,S9,S17,S18) and monitored with UV-spectroscopy 
and ICP-OES; each of the isolated solid phase contains a mixture of 1+Pir (Form III) and 2+PIR (Form 
III), corroborating that the equilibrium mixtures are both stable in solution. Table 2 lists the 
concentration values (Ceu) of co-crystals components as well as the solubility constants (Ksp) relative 
to the slurry of ICCs (method 1) and the eutectic approach (method 2) carried out on 1 and 2. Ksp 
values are in good agreement with each other (calcultated from method 1 and 2), corroborating the 
goodness of the measurements performed applying both methods. The fact that the [salts]eu is 
below the [PIR]eu confirm, one time again, that 1 and 2 are less soluble than pure piracetam, 
according to the eutectic constant (Keu) rules [1d]. Keu (see figure 1), is a good indicator of co-crystal 
solubility and stability; its value is below 1.0 when the co-crystal is congruently saturated (less 
soluble than the pure drug)[1]; this assumption is valid for co-crystals with stoichiometric ratio 1:1. 
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In figure 1 is shown a clear relationship between cocrystal components and cocrystal solubility. This 
suggests that Keu values increase with the increasing of the solubility ratio salt/PIR, suggesting the 
possibility to design specific solution properties -like solubility- choosing right co-crystal 
components, as required.  
 
 
 
 
 
 
Figure 1. Qualitative relationship between Keu and the intrinsic solubility ratio salts/piracetam.  
Ionic Co-Crystals – PIR2∙CaCl2∙2(H2O) (3) and PIR2∙SrCl2∙3(H2O) (4)  
Solubility in water 
Upon kneading of piracetam with SrCl2 ∙ 6(H2O), a new crystalline phase was produced (different 
from that present in the literature [ref.]) and attributed to an ICC with a different degree of 
hydration [PIR2∙SrCl2∙3(H2O) – see SI – figures S50,S51]. Solubility in water was calculated performing 
slurry of 3 and 4 respectively (method 1). Each solid phase obtained was monitored through XRPD 
and DSC analysis; no transition to the pure drug was observed, confirming that also 3 and 4 are less 
soluble than the pure drug. Solubility in water of 3 was also investigated using the eutectic approach 
(method 2)— see SI – figures S10-12,S15,S16,S19; the results are in good agreement with that 
obtained from method 1 (see table 2). Unfortunately, it was not possible to apply the eutectic 
approach also on the ICC 4.  
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Co-formers that increase solubility of piracetam 
[PIR]eu of 2, unlike that referred to 1, reached a value significantly higher than the intrinsic solubility 
of piracetam. In this regard, a suspension of piracetam in water was prepared and subsequent 
addition of LiBr caused an improvement of solubility of piracetam, up to a complete dissolution of 
the precipitate. Solute-solute and solvent-solute interactions stabilize the supersaturated solution, 
at least for one week, up to a concentration limit of piracetam more than twice the intrinsic solubility 
(8,7 x 100  ± 1 x 10-1 M). Beyond this concentration, crystallization of 2 occurred because it is less 
soluble than the drug (see SI – figure S48), acting as a limiting reagent for the stability of the system 
(Figure 2). Adding more piracetam to the system, we were able to build experimentally the solubility 
curve of 2 reaching the eutectic point (7,8 x 100  ± 4 x 10-2 M), in which both solid phases of 2 and 
piracetam were in equilibrium with the aqueous solution [see Si – figure S49]. The relative 
concentration values of LiBr were calculated starting from the Ksp calculated from method 1.  
Figure 2. Slurry experiment of piracetam with addition of LiBr. 
CaCl2, on the other hand, has almost no effect on the drug solubility, with [PIR]eu (4,9 x 100 ± 7 x 10-
3 M) slightly above PIR solubility in pure solvent (3,7 x 100  ± 3 x 10-3 M). The solubilizing effect on 
the drug appears to depend on the solubility of the salts. The [salts]eu values follow the salts 
solubility (LiCl ~ LiBr > CaCl2); this trend is partially reversed if we consider the improvement of drug 
solubility represented by the value of [PIR]eu (LiBr > CaCl2 > LiCl) – see Table 2 [1b]. In figure 3 are 
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shown the solubility curves calculated from method 2 (for 1, 2 and 3) and from method 1 (for 4); 2 
is the most soluble, followed by 1, 4 and 3. It is evident that, keeping invariant the molecule of 
interest and the nature of the interactions in solution, the type of salt affects the solubility of the 
co-crystal. Lithium chloride and lithium bromide, being more soluble than calcium chloride and 
strontium chloride, influence more the equilibria in solution in terms of solute-solute and solvent-
solute interactions, increasing the stability in solution of the ICCs. 
 
Figure 3. Solubility curves calculated from eutectic measurements (for 1, 2 and 3) and from slurry of ICC (4). 
Ionic Co-Crystals – 1-2-3-4 – Solubility in ethanol 
Slurry experiments (method 1) of 1,2,3,and 4 were carried out. The solid phase of each sample was 
daily monitored through XRPD and DSC analysis, up to no changes were observed for at least 72h 
(see SI – figures S20-S27). Slurry experiments (13 days) of 4 showed a complete transition from 4 to 
another unknown phase probably corresponding to a crystalline phase with different degree of 
hydration (see SI – Figure S23). Analogously to the ICCs in aqueous media, no transition to the drug 
was observed, suggesting that all ICCs are less soluble than the drug. In table 3 are listed the 
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experimental results, and the solubility ratios of Sdrugcc/Sdrugintrinsic relative to 1 and 2 are 3,7 and 
3,8 respectively. There is a remarkable solubilizing effect of piracetam more evident than in water. 
This is probably due to the lower intrinsic solubility of piracetam in ethanol than in water, combined 
with the presence of traces of water (0,2% of water-Sigma Aldrich reference) and of the salts (LiCl 
and LiBr). Figure 4 shows the solubility curves calculated from method 1 of 1, 2, 3 and 4; also in this 
case, 1 and 2 (figure 4a) are more soluble than 3 and 4 (figure 4b). The same hypothesis advanced 
about the solubility of the ICCs in water, is also valid in this case. 
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(b) 
Figure 4. Solubility curves in EtOH calculated from method 1 on (a) 1, 2 and (b) 3 and ICC∙SrCl2∙X(H2O). 
 
Deliquescence relative humidity: stability studies 
Piracetam together with 1, 2, 3 and 4 were stored (for 8 days) at different relative humidity levels 
(RH%), in order to measure the deliquescence relative humidity. The deliquescence point 
corresponds to the critical relative humidity (DHR), at which the solid starts to dissolve up to 
saturation. [5] 
The DHR% values of piracetam as well as that of ICCs are shown in figure 5. Piracetam, although 
highly soluble in water, has an high deliquescence point (85%). This is very interesting because 
deliquescent materials are typically crystalline solids that are highly water soluble.[5b,c] DHR% 
values of ICCs lie between that of piracetam and the relative salt, keeping high the value of 
deliquescent point (1-53%, 2-54%, 3-78%, 4-55%). There are additional changes in slope for the 
systems 1, 2 and 4 probably due to the kinetics of dissolution at DRH point. The solid phase, relative 
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to each saturated solution, was investigated by XRPD and DSC; no transition to other crystalline 
phases occurred (see SI – figures S28-S47). 
 
Figure 5. Deliquescence point of piracetam,1,2,3 and 4. 
 
These experimental results have been compared with DHR% predicted from the Ross equation[5], 
optimized for a mixture. All ICCs, except for 4, are composed by high deliquescent salts and, 
according to the Ross equation, the deliquescent point should be lower than that of the mixture 
components; indeed, there is a spread between experimental and predicted values for 1,2 and 3 
(see table 4). Experimental deliquescence point of all ICCs is an ”averaged” value between the DHR 
values of the co-crystal components. Ross suggested an empirical interaction parameter (χ) to 
represent the contribution of solute-solute and solvent-solute interactions to the DHR value of the 
product. χ parameter corresponds to the ratio DHR%(observed)/ DHR%(calculated) ; the ratio is much 
greater than one for 1, 2 and 3  but not for 4, for which it is closed to one (table 4). This probably 
happens because the components are co-crystallized, but also for the hygroscopicity of the salts. 
LiCl, LiBr and CaCl2, unlike of SrCl2, are hygroscopic and they are stabilized in term of hygroscopicity, 
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upon co-crystallization with piracetam. This is a clear example of how the solution chemistry is 
reflected in the solid-state properties, suggesting the possibility to formulate deliquescent drugs, 
exploiting the stabilization effect due to the co-crystallization with non-hygroscopic active 
molecules without using further excipients. 
 
Table 4. DHR% observed vs predicted  
 DHR1% (observed) DHR% (predicted) χ 
Piracetam 85   
PIR∙LiCl∙2(H2O) 53 9,3 5,7 
PIR∙LiBr∙2(H2O) 54 5,1 10,6 
PIR2∙CaCl2∙2(H2O) 78 25,5 3,1 
PIR2∙SrCl2∙3(H2O) 55 60,3 0,91 
  
 
2.3.4 Conclusions 
 
All ICCs are less soluble than the pure piracetam, both in H2O and EtOH. Slurry (method 1) and 
eutectic approach (method 2) methods are consistent with each others. A solubilizing effect of the 
piracetam, up to four times the intrinsic solubility, was observed, upon addition in solution of  
inorganic salts (co-formers of piracetam in the ICCs). There is a synergic effect between the ion 
paring phenomenon and the solvating effect of the drug molecule in competition with water 
molecules for ions coordination, as it is observed in the solid state with the ICCs. Piracetam and its 
ICCs are stable also at high RH%; there is also a stabilization effect of co-crystallization on salts (LiCl 
in particular) in terms of hygroscopicity. The deliquescent point of the ICCs, predicted from Ross 
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equation, differs from that observed due probably to significant solute-solute interactions for PIR ∙ 
LiCl ∙ 2(H2O), PIR ∙ LiBr ∙ 2(H2O) and PIR2 ∙ CaCl2 ∙ 2(H2O); this is unsurprising, given the high 
concentrations involved. We can state that the main aspects of the solid state properties of ICCs are 
mirrored in solution, resulting in the modification of stability in solution of the drug under 
investigation, once co-crystallized. This proves one time again how the investigation of solid state 
properties can be a resource to figure out what is going on in solution and also to design in solid 
what we are interested to obtain in solution. Piracetam, given its intrinsic high solubility and 
permeability (bioavailability 100%), was used as a learning model for other systems less soluble 
and/or permeable, with the aim to choose right co-formers depending on the final requirements. 
Ionic co-crystals can be a valuable resource to improve not only the solubility but also, in certain 
cases, the permeability,[6] with the final aim to improve the bioavailability of the molecule of 
interest. 
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Table 2. Cocrystal eutectic concentrations ([drug]eu and [ligand]eu), Component Solubilities, and Calculated 
Cocrystal Ksp Values, Solubilities, and Solubility Ratios in water. 
 
 
Solubility ratio 
[drug]s cc/Sdrug 
0,9 1,1 0,6 0,8 
Ionic co-crystal 
solubility  (M) eu 
3,4 x 100  4,2 x 100  1,2 x 100  - 
Ionic co-crystal 
solubility  (M) slurry 
3,6 x 100  4,2 x 100  1,1 x 100  1,4 x 100   
Ksp eutectic approach 
(2nd method) 
3,8 x 101  M3 7,5 x 101  M3 3,2 x 101  M5 - 
Ksp slurry (1st 
method) 
4,6 x 101 M3 7,7 x 101 M3 2,5 x 101 M5 7,5 x 101 M5 
Sdrug (M) 3,7 x 100 ± 3 x 
10-3 
3,7 x 100 ± 3 x 
10-3 
3,7 x 100 ± 3 x 10-
3 
3,7 x 100 ± 3 x 10-
3 
Sligand (M) 19,9 x 100 ± 3 x 
10-3 
17 x 100 ± 2 x 
10-4 
7,5 x 100 ± 3 x 10-
3 
3,5 x 100 ± 2 x 10-
4 
[ligand]eu(mean ± 
range) 
3,1 x 100 ± 4 x 
10-2 
3,1 x 100 ± 3 x 
10-3 
1,1 x 100 ± 5 x 10-
3 
- 
[PIR]eu(M) (mean ± 
range) 
4 x 100 ± 1 x 10-
2 
7,8 x 100 ± 4 x 
10-2 
4,9 x 100 ± 7 x 10-
3 
- 
[ligand]slurry (M) 
(mean ± range) 
3,8 x 100 ± 4 x 
10-2 
3,6 x 100 ± 3 x 
10-2 
- - 
[PIR]slurry(M) (mean ± 
range) 
3,1 x 100 ± 2 x 
10-2 
5,8 x 100 ± 4 x 
10-3 
2,9 x 100 ± 4 x 10-
3 
3,6 x 10-1± 3 x 10-
2 
Solvent H2O H2O H2O H2O 
A:B 
ICC stoichiometry 
(drug- ligand) 
1:1 1:1 2:1 2:1 
Ionic co-crystal PIR∙LiCl∙2(H2O) PIR∙LiBr∙2(H2O) PIR2∙CaCl2∙2(H2O) PIR2∙SrCl2∙3(H2O) 
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Table 3. Cocrystal components concentrations, component Solubilities, Calculated Cocrystal Ksp Values, 
Solubilities, and Solubility Ratios in EtOH. 
  
 
 
 
 
 
 
 
 
 
Solubility ratio 
[drug]s cc/Sdrug 
3,7 3,8 0,2 0,7 
Ionic co-crystal 
solubility  (M) slurry 
8,2 x 10-1  8,4 x 10-1  2,2 x 10-2  7,2 x 10-2  
Ksp slurry ICC (1st 
method) 
5,5 x 10-1 M3 5,9 x 10-1 M3 8,4 x 10-8 M5 3,1x 10-5 M5 
Sdrug (M) 2,2 x 10-1 ± 2 x 10-
4 
2,2 x 10-1 ± 2 x 10-
4 
2,2 x 10-1 ± 2 x 10-
4 
2,2 x 10-1 ± 2 x 
10-4 
Sligand (M) 7,4 x 100 ± 3 x 10-
3 
7,3 x 100 ± 2 x 10-4 2,3 x 100 ± 3 x 10-
3 
2,2 x 10-1 ± 2 x 
10-4 
[ligand]slurry (M) 
(mean ± range) 
- - - - 
[PIR]slurry(M) (mean ± 
range) 
8,2 x 10-1 ± 3 x 10-
3 
8,4 x 10-1 ± 4 x 10-
3 
5,9 x 10-2 ± 7 x 10-
6 
1,9 x 10-1± 6 x 10-
4 
Solvent Ethanol Ethanol Ethanol Ethanol 
A:B 
ICC stoichiometry 
(drug- ligand) 
1:1 1:1 2:1 2:1 
Ionic co-crystal PIR∙LiCl∙2(H2O) PIR∙LiBr∙2(H2O) PIR2∙CaCl2∙2(H2O) PIR2∙SrCl2∙X(H2O) 
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SUPPORTING INFORMATION 
 
XRPD patterns of piracetam and the ICCs - PIR∙LiCl∙2(H2O)(1), PIR∙LiBr∙2(H2O) (2), 
PIR2∙CaCl2∙2(H2O) (3) and PIR2∙SrCl2∙3(H2O) (4). [2] 
5 10 15 20 25 30 35 40
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Figure S1. X-ray powder diffraction patterns observed for Piracetam  (PIR,  form  III), 1, 2, 3 and 4 . 
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DSC measurements (3-6 mg - sealed pan) of the ICCs - PIR∙LiCl∙2(H2O)(1), 
PIR∙LiBr∙2(H2O) (2), PIR2∙CaCl2∙2(H2O) (3) and PIR2∙SrCl2∙3(H2O) (4). [2]  
 
Figure S2. DSC measurement of 1; heating rate 5°C/min 
 
Figure S3. DSC measurement of 2. RT  130°C heating rate 10°C/min, 130°C  160°C heating rate 2°C/min, 
160°C  200°C heating rate 15°C/min.  
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Figure S4. DSC measurement of 3; heating rate 5°C/min. 
 
 
 
Figure S5. DSC measurement of 4; heating rate 5°C/min. 
 
 
 
 
 
 
Broad peak probably due to 
the loss of H
2
O of ICC + 
melting and decomposition 
of the anhydrous form 
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Ionic Co-Crystals (1), (2), (3) and (4). Solubility studies in H2O 
XRPD patterns of 1 and 2. 
1st method  
 
 
5 10 15 20 25 30 35 40
 PIR*LiCl*2(H2O)
 PIR*LiCl*2(H2O) after slurry
2/deg
 
Figure S6. X-ray powder diffraction patterns observed for 1 (black trace) and 1 after slurry in water (1 s t 
method) (red trace) . 
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5 10 15 20 25 30 35 40
PIR*LiBr*2(H2O) 
 PIR*LiBr*2(H2O) slurry
2/deg
 
Figure S7. X-ray powder diffraction patterns observed for 2 (black trace) and 2 after slurry in water (1 s t 
method) (red trace).
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2nd method  
 
5 10 15 20 25 30 35 40
 PIR*LiCl*2(H2O)
 PIR*LiCl*2(H2O)+PIR_2
nd
method
 PIR_Form III
2/deg
 
Figure S8. X-ray powder diffraction patterns observed for 1 (black trace) , slurry in water of 1  and 
piracetam (2nd method- red trace) and piracetam (PIR- form III – blue trace). 
 
5 10 15 20 25 30 35 40
 PIR*LiBr*2(H2O)
 PIR Form III
 PIR*LiBr*2(H2O) + PIR_FormIII
2/deg
 
Figure S9. X-ray powder diffraction patterns observed for 2 (black trace) , slurry in water of 2  and 
piracetam  (2nd method- red trace) and piracetam (PIR- form III – blue trace). 
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XRPD patterns of 3 and 4. 
1st method  
0 5 10 15 20 25 30 35 40 45
 PIR
2
*CaCl
2
*2H
2
Oafter slurry
 PIR
2
*CaCl
2
*2H
2
O
2/deg
 
Figure S10. X-ray powder diffraction patterns observed for 3 (black trace) vs 3 after slurry in water 
(1s t method)  (red trace). 
 
5 10 15 20 25 30 35 40
 PIR
2
*SrCl
2
*3H
2
O after slurry
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2
*SrCl
2
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2
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2
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Figure S11. X-ray powder diffraction patterns observed for 4 (red trace),  4 after slurry in water (1 s t 
method) (black trace) and PIR2SrCl2∙2H2O (blue trace). 
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2nd method  
 
5 10 15 20 25 30 35 40
 PIR
2
*CaCl
2
*2H
2
O
 PIR
2
*CaCl
2
*2H
2
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 PIR_formIII
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Figure S12. X-ray powder diffraction patterns observed for 3 (blue trace), slurry in water of 3  and 
piracetam (2nd method- red trace) and piracetam (PIR- form III – black trace). 
 
DSC measurements of 1, 2, 3 and 4. 
1st Method 
 
Figure S13. DSC measurement of 1; RT  130°C heating rate 10°C/min, 130°C  160°C heating rate 2°C/min, 
160°C  200°C heating rate 15°C/min. 
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Figure S14. DSC measurement of 2. RT  130°C heating rate 10°C/min, 130°C  160°C heating rate 2°C/min, 
160°C  200°C heating rate 15°C/min. 
 
 
Figure S15. DSC measurement of 3; heating rate 5°C/min. 
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Figure S16. DSC measurement of 4; heating rate 5°C/min. 
 
2nd Method 
 
Figure S17. DSC measurement of 1 + PIR ; heating rate 5°C/min. 
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Figure S18. DSC measurement of 2 + PIR ; heating rate 5°C/min. 
 
 
 
Figure S19. DSC measurement of 3 + PIR ; heating rate 5°C/min. 
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Ionic Co-Crystals (1), (2), (3) and (4). Solubility studies in EtOH 
 
XRPD patterns of 1, 2, 3 and 4. 
5 10 15 20 25 30 35 40
 PIR*LiCl*2(H2O) after slurry
 PIR*LiCl*2(H2O)
2/deg
 
Figure S20. X-ray powder diffraction patterns observed for 1 (black trace) vs 1 after slurry in 
ethanol (1 s t method) (red trace) . 
 
5 10 15 20 25 30 35 40
PIR*LiBr*2(H2O) 
 PIR*LiBr*2(H2O) slurry
2/deg
 
Figure S21. X-ray powder diffraction patterns observed for 2 (black trace) vs 2 after slurry in 
ethanol (1 s t method) (red trace) . 
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5 10 15 20 25 30 35 40
PIR
2
*CaCl
2
*2(H2O) 
 PIR
2
*CaCl
2
*2(H2O) slurry
2/deg
 
Figure S22. X-ray powder diffraction patterns observed for 3 (black trace) vs 3 after slurry in 
ethanol (1 s t method) (red trace) . 
 
5 10 15 20 25 30 35 40
 PIR
2
*SrCl
2
*3(H2O) (kneading EtOH)
 PIR
2
*SrCl
2
*2(H2O) (cryst from EtOH)
 slurry PIR
2
*SrCl
2
*3(H2O) in EtOH
2deg
 
Figure S23. X-ray powder diffraction patterns observed for 4 (red trace),  phase X after slurry of 4 in 
ethanol (13days - 1s t method) (black trace) and PIR2SrCl2∙2H2O (blue trace). 
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DSC measurements of 1, 2, 3 and 4. 
 
 
 
 
Figure S24. DSC measurement of 1 after slurry in ethanol ; heating rate 5°C/min. 
 
 
 
Figure S25. DSC measurement of 2 after slurry in ethanol; RT  130°C heating rate 10°C/min, 130°C  
160°C heating rate 2°C/min, 160°C  200°C heating rate 15°C/min. 
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Figure S26. DSC measurement of 3 after slurry in ethanol; heating rate 5°C/min. 
 
 
Figure S27. DSC measurement of 4 after slurry in ethanol (13days); heating rate 5°C/min. 
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Deliquescence relative humidity: stability studies 
XRPD patterns of 1, 2, 3 and 4. 
 
5 10 15 20 25 30 35 40
 PIR_RH 22%
 PIR_RH 42%
 PIR_RH 64%
 PIR_RH 75%
 PIR_RH 84%
2/deg
 
Figure S28. X-ray powder diffraction patterns observed for PIR exposed to  RH 22% (black trace),  RH 
42% (red trace), RH 64% (blue trace) , RH 75% (green trace), RH 84% (orange trace) 
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Figure S29. X-ray powder diffraction patterns observed for 1 exposed to  RH 11% (black trace),  RH 
22% (red trace) and RH 42% (blue trace) . 
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5 10 15 20 25 30 35 40
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O_RH 11%
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2
O_RH 22%
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2/deg
 
Figure S30. X-ray powder diffraction patterns observed for 2 exposed to  RH 11% (black trace),  RH 
22% (red trace) and RH 42% (blue trace) . 
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Figure S31. X-ray powder diffraction patterns observed for 3 exposed to  RH 22% (black trace),  RH 
42% (red trace),  RH 64% (blue trace) and RH 75% (green trace) . 
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Figure S32. X-ray powder diffraction patterns observed for 4 exposed to  RH 11% (black trace),  RH 
22% (red trace) and RH 42% (blue trace) and RH 64% (green trace) . 
 
DSC measurements of 1, 2, 3 and 4. 
 
 
Figure S33. DSC measurement of PIR exposed to RH 22%; heating rate 5°C/min. 
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Figure S34. DSC measurement of PIR exposed to RH 42%; heating rate 5°C/min. 
 
 
Figure S35. DSC measurement of PIR exposed to RH 64%; heating rate 5°C/min. 
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Figure S36. DSC measurement of PIR exposed to RH 84%; heating rate 5°C/min. 
 
 
Figure S37. DSC measurement of 1 exposed to RH 11%; heating rate 5°C/min. 
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Figure S38. DSC measurement of 1 exposed to RH 22%; heating rate 5°C/min. 
 
 
Figure S39. DSC measurement of 1 exposed to RH 42%; heating rate 5°C/min. 
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Figure S40. DSC measurement of 2 exposed to RH 11%; heating rate 5°C/min. 
 
 
 
Figure S41. DSC measurement of 2 exposed to RH 22%; heating rate 5°C/min. 
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Figure S42. DSC measurement of 2 exposed to RH 42%; heating rate 5°C/min. 
 
 
Figure S43. DSC measurement of 3 exposed to RH 22%; heating rate 5°C/min. 
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Figure S43. DSC measurement of 3 exposed to RH 42%; heating rate 5°C/min. 
 
 
Figure S44. DSC measurement of 3 exposed to RH 64%; heating rate 5°C/min. 
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Figure S45. DSC measurement of 3 exposed to RH 75%; heating rate 5°C/min. 
 
 
 
Figure S46. DSC measurement of 4 exposed to RH 22%; heating rate 5°C/min. 
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Figure S47. DSC measurement of 4 exposed to RH 42%; heating rate 5°C/min. 
 
 
Co-formers that increase the solubility of piracetam 
5 10 15 20 25 30 35 40
 PIR*LiBr*2(H
2
O) precipitate from solution 
 PIR*LiBr*2(H
2
O) from grinding
2/deg
 
Figure S48. X-ray powder diffraction patterns observed for 2 (black trace) and  2 precipitate from aqueous 
solution  (red trace) . 
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5 10 15 20 25 30 35 40
 PIR*LiBr*2(H
2
O) observed from grinding
 PIR*LiBr*2(H
2
O) + PIR(III) 
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2/deg
 
Figure S49. X-ray powder diffraction patterns observed for PIR-Form III  (black trace), 2 (red trace)  and 2 + 
PIR-form III  (blue trace).  
 
Crystal structure determination of PIR2∙SrCl2∙3(H2O) from single crystal data 
(crystallized from H2O) 
 
Figure S50. Crystalline packing of 4 – view down the a-axis. 
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Figure S51. X-ray powder diffraction patterns calculated for 4 (black trace)  and observed for 4 (red 
trace). 
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2.4  COMBINING PIRACETAM AND LITHIUM SALTS: IONIC CO-CRYSTALS 
AND CO-DRUGS?* 
 
Ionic co-crystals of piracetam with the inorganic salts LiCl and LiBr were synthesized through solid 
state reactions (grinding and kneading) and from solution as well. Ionic co-crystal are crystalline 
materials composed by organic molecule and inorganic salts of alkaline and alkaline earth metals, 
and stabilized by synergic action of organic and inorganic interactions. Crystallization from water 
solutions of piracetam with LiCl and LiBr yield crystalline materials of PIR∙LiCl∙2(H2O) and 
PIR∙LiBr∙2(H2O) respectively. PIR∙LiBr∙2(H2O) was found to be isomorphous with PIR∙LiCl∙2(H2O). 
Kneading of Piracetam with LiCl produced two crystalline phases corresponding to PIR∙LiCl∙2(H2O) 
and the relative anhydrous form. The physical-chemical properties of these two crystalline forms in 
addition to PIR∙LiBr∙2(H2O) have been studied  and characterized by single crystal and powder X-ray 
diffraction at variable temperatures, DSC, TGA, hot stage microscopy (HSM) and intrinsic dissolution 
rate (IDR). The ionic co-crystals studied have different properties with respect to pure components 
especially in terms of thermal stability. Moreover, it was observed that the thermal relationships 
between hydrate and anhydrous form of the ionic co-crystals with LiCl also depend on the method 
for preparation and/or on the conditions of measurements. It confirms, on the other hand, that the 
thermal techniques used to characterize the systems of interest are complementary each other and 
give only a part of the overall information. In this regard, also the role of the intrinsic properties of 
the crystalline phase such as crystallinity and size (milli metric or micrometric) of the crystals is 
important and it is still a forefront topic open at new perspective.  
*D. Braga, F. Grepioni, L. Maini, D. Capucci, S. Nanna, J. Wouters, L. Aerts and L. Quéré, Chem. 
Commun., 2012, 48, 8219–8221  
 
For copyright reasons only the link to the original article is reported here: 
http://pubs.rsc.org/en/content/articlelanding/2012/cc/c2cc33855f#!divAbstract 
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2.5 IMAZAMOX: A QUEST FOR POLYMORPHIC MODIFICATIONS OF A 
CHIRAL AND RACEMIC HERBICIDE* 
 
Chiral and racemic imazamox was characterized and assessed in solid state. In detail, crystal 
structure of four polymorphs of chiral imazamox were solved and thermally characterized. 
Moreover, we were able to identify the thermodynamically stable forms at room and high 
temperatures. In addition, the adoption of salts in the crystallization media has had positive effects, 
allowing the production of new polymorphs with different morphologies/sizes of the crystal. 
Potential polymorphs in agrochemical field, induced by different crystallization environment, can be 
interesting in the process of identifying stable forms during industrial production processes.  
*Dario Braga , Laura Chelazzi, Fabrizia Grepioni , Saverio Nanna, Katia Rubini, Marco Curzi, Stefano 
Giaffreda, Heidi E. Saxell, Matthias Bratz, and Tiziana Chiodo, Cryst. Growth Des., 2014, 14 (3), pp 1430–
1437 
 
 
For copyright reasons only the link to the original article is reported here: 
 
http://pubs.acs.org/doi/abs/10.1021/cg4019025 
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2.6  BENTAZON: EFFECT OF ADDITIVES ON THE CRYSTALLIZATION OF 
PURE AND MIXED POLYMORPHIC FORMS OF A COMMERCIAL HERBICIDE* 
 
After polymorph screening studies on the bentazon molecule, two different polymorphs, Forms II and 
III (Form I already reported in literature), were isolated and characterized with X-ray single crystal 
diffraction, X-ray powder diffraction (XRPD), variable temperature X-ray powder diffraction 
(VTXRPD), differential scanning calorimetry (DSC), and hot-stage microscopy (HSM). Unlike the 
pharmaceutical field, the investigation of agrochemical compounds in solid state is very interesting, 
being a relatively unexplored field. Indeed, a better understanding of the solid state properties of 
these unexplored crystalline forms can represent a resource for the industry and a challenge for solid-
state chemists. 
Dario Braga, Fabrizia Grepioni , Laura Chelazzi, Saverio Nanna, Katia Rubini, Marco Curzi, Stefano L. 
Giaffreda, Heidi E. Saxell, Matthias Bratz, and Tiziana Chiodo, Cryst. Growth Des., 2014, 14 (11), pp 5729–
5736. 
 
 
 
 
For copyright reasons only the link to the original article is reported here: 
 
http://pubs.acs.org/doi/abs/10.1021/cg500980j 
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2.7 IONIC CO-CRYSTALS OF RACETAMS: SOLID-STATE PROPERTIES 
ENHANCEMENT OF NEUTRAL ACTIVE PHARMACEUTICAL INGREDIENTS 
VIA ADDITION OF MG2+ AND CA2+ CHLORIDES* 
 
Mechanochemical and solution based reactions between brivaracetam (BRV) or seletracetam (SEL) 
and calcium or magnesium salts (CaCl2 and MgCl2) have been conducted yielding ionic co-crystals. 
These new materials showed different/improved physical-chemical properties with respect to pure 
drug in terms of thermal stability, hygroscopicity and crystal morphology. Furthermore, the 
relationship between crystal structures and properties was investigated. “BRV2·MgCl2·4H2O and 
SEL2·MgCl2·4H2O co-crystals present an octahedral coordination of Mg2+ within polymeric chains, 
forming a crystal lattice constituted by lipophilic multilayers”. After co-crystallization of BRV and SEL 
with MgCl2 and CaCl2 changes in the morphology of the crystals were observed as well as different 
thermal stability was observed respectively. All ionic co-crystals were characterized via a 
combination of solid-state techniques, i.e. single crystal and powder X-ray diffraction, variable 
temperature X-ray diffraction, DSC, TGA and hot-stage microscopy (HSM). In addition to thermal 
stability, changes in hygroscopicity and crystal morphology were observed; indeed, these differences 
could play a key role not only in the industrial production processes but also in the storage 
operations.  
*Fabrizia Grepioni, Johan Wouters, Dario Braga, Saverio Nanna, Baptiste Fours, Gérard Coquerel, Geraldine 
Longfils, Sandrine Rome, Luc Aertse and Luc Quére, CrystEngComm, 2014,16, 5887-5896. 
 
 
 
For copyright reasons only the link to the original article is reported here: 
 
http://pubs.rsc.org/en/content/articlelanding/2014/ce/c4ce00409d#!divAbstract 
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SUMMARY 
 
The aim of this PhD thesis was:  
“Optimization of molecular and crystalline forms of drugs, agrochemicals, pesticides in relation to 
activity, bioavailability, patentability and to the fabrication of polymorphs, solvates, co-crystals 
with green chemistry methods” 
During these three years, each project carried out concerned a part of the overall target. Below are 
summarized the main results obtained for each project. 
Folic acid: an investigation of solid-state properties and crystal forms.  
The structure of folic acid was solved by XRPD and the high temperature phase was reported.  
“Amorphous Salts” and “amorphous ionic co-crystals” of folic acid with inorganic salts were 
synthesized by solvent free methods and characterized by TGA/DSC and their intrinsic dissolution 
rate were tested. This study highlights the importance of using different routes of preparation to 
obtain “new” APIs. In particular, the solid-solid reaction can be used to produce new forms with 
different physical chemical properties. This aspect together with the possibility to obtain stable 
amorphous phase over time, without changing the chemical entity, could be an interesting way to 
obtain new useful results in the pharmaceutical field.  
 
Folic acid revisited: a synergic computational, spectroscopic and structural approach 
in the solid-state.  
In this paper was pointed out how the synergic combination of different techniques at the solid state 
could be a power-full tool to solve complicated structural problems. The structure of folic acid was 
solved with X-ray powder diffraction and ab initio calculations reporting for the first time the Raman 
spectra with peaks assignment too. 
Ionic co-crystals of piracetam: from solid to solution 
 All ICCs are less soluble than the pure piracetam both in H2O and EtOH. Slurry (method 1) and 
eutectic approach (method 2) methods are consistent each others. A solubilizing effect of the 
piracetam, until four times the intrinsic solubility, was observed, adding in solution inorganic salts 
(co-formers of piracetam in the ionic co-crystals - ICCs). There is a synergic effect between ion paring 
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phenomenon and the solvating effect of the drug molecule in a competition with water molecules 
for ions coordination, as it is observed in solid state with the ICCs. Piracetam and its ICCs are stable 
also at high RH%; there is also a stabilization effect of co-crystallization on salts (LiCl in particular) in 
terms of hygroscopicity. The deliquescent point of the ICCs, predicted from Ross equation, differs 
from that observed due probably to significant solute-solute interactions for PIR ∙ LiCl ∙ 2(H2O), PIR ∙ 
LiBr ∙ 2(H2O) and PIR2 ∙ CaCl2 ∙ 2(H2O); this is unsurprising, given the high concentrations involved. 
We can state that the main aspects of the solid state properties of ICCs are mirrored in solution, 
resulting in the modification of stability in solution of the drug under investigation, once co-
crystallized. This proves one time again how the investigation of solid state properties can be a 
resource to figure out what is going on in solution and also to design in solid what we are interested 
to obtain in solution. Piracetam, given its intrinsic high solubility and permeability (bioavailability 
100%), was used as a learning model for other systems less soluble and/or permeable, with the aim 
to choose right co-formers depending on the final requirements. Ionic co-crystals can be a valuable 
resource to improve not only the solubility but also, in certain cases, the permeability, with the final 
aim to improve the bioavailability of the molecule of interest. 
Combining piracetam and lithium salts: ionic co-crystals and co-drugs? 
 
Ionic co-crystals of piracetam with the inorganic salts LiCl and LiBr were synthesized through solid 
state reactions (grinding and kneading) and from solution as well. Ionic co-crystal are crystalline 
materials composed by organic molecule and inorganic salts of alkaline and alkaline earth metals, 
and stabilized by synergic action of organic and inorganic interactions. Crystallization from water 
solutions of piracetam with LiCl and LiBr yield crystalline materials of PIR∙LiCl∙2(H2O) and 
PIR∙LiBr∙2(H2O) respectively. PIR∙LiBr∙2(H2O) was found to be isomorphous with PIR∙LiCl∙2(H2O). 
Kneading of Piracetam with LiCl produced two crystalline phases corresponding to PIR∙LiCl∙2(H2O) 
and the relative anhydrous form. The physical-chemical properties of these two crystalline forms in 
addition to PIR∙LiBr∙2(H2O) have been studied  and characterized by single crystal and powder X-ray 
diffraction at variable temperatures, DSC, TGA, hot stage microscopy (HSM) and intrinsic dissolution 
rate (IDR). The ionic co-crystals studied have different properties with respect to pure components 
especially in terms of thermal stability. Moreover, it was observed that the thermal relationships 
between hydrate and anhydrous form of the ionic co-crystals with LiCl also depend on the method 
for preparation and/or on the conditions of measurements. It confirms, on the other hand, that the 
thermal techniques used to characterize the systems of interest are complementary each other and 
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give only a part of the overall information. In this regard, also the role of the intrinsic properties of 
the crystalline phase such as crystallinity and size (milli metric or micrometric) of the crystals is 
important and it is still a forefront topic open at new perspective.  
 
Imazamox: A Quest for Polymorphic Modifications of a Chiral and Racemic Herbicide 
 
Chiral and racemic imazamox was characterized and assessed in solid state. In detail, crystal 
structure of four polymorphs of chiral imazamox were solved and thermally characterized. 
Moreover, we were able to identify the thermodynamically stable forms at room and high 
temperatures. In addition, the adoption of salts in the crystallization media has had positive effects, 
allowing the production of new polymorphs with different morphologies/sizes of the crystal. 
Potential polymorphs in agrochemical field, induced by different crystallization environment, can be 
interesting in the process of identifying stable forms during industrial production processes.  
 
Bentazon: Effect of Additives on the Crystallization of Pure and Mixed Polymorphic 
Forms of a Commercial Herbicide 
 
After polymorph screening studies on the bentazon molecule, two different polymorphs, Forms II and 
III (Form I already reported in literature), were isolated and characterized with X-ray single crystal 
diffraction, X-ray powder diffraction (XRPD), variable temperature X-ray powder diffraction 
(VTXRPD), differential scanning calorimetry (DSC), and hot-stage microscopy (HSM). Unlike the 
pharmaceutical field, the investigation of agrochemical compounds in solid state is very interesting, 
being a relatively unexplored field. Indeed, a better understanding of the solid state properties of 
these unexplored crystalline forms can represent a resource for the industry and a challenge for solid-
state chemists. 
 
Ionic co-crystals of racetams: solid-state properties enhancement of neutral active 
pharmaceutical ingredients via addition of Mg2+ and Ca2+ chlorides 
 
Mechanochemical and solution based reactions between brivaracetam (BRV) or seletracetam (SEL) 
and calcium or magnesium salts (CaCl2 and MgCl2) have been conducted yielding ionic co-crystals. 
These new materials showed different/improved physical-chemical properties with respect to pure 
drug in terms of thermal stability, hygroscopicity and crystal morphology. Furthermore, the 
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relationship between crystal structures and properties was investigated. “BRV2·MgCl2·4H2O and 
SEL2·MgCl2·4H2O co-crystals present an octahedral coordination of Mg2+ within polymeric chains, 
forming a crystal lattice constituted by lipophilic multilayers”. After co-crystallization of BRV and SEL 
with MgCl2 and CaCl2 changes in the morphology of the crystals were observed as well as different 
thermal stability was observed respectively. All ionic co-crystals were characterized via a 
combination of solid-state techniques, i.e. single crystal and powder X-ray diffraction, variable 
temperature X-ray diffraction, DSC, TGA and hot-stage microscopy (HSM). In addition to thermal 
stability, changes in hygroscopicity and crystal morphology were observed; indeed, these differences 
could play a key role not only in the industrial production processes but also in the storage 
operations.  
 
The results relative to the published papers and those that are going to be published are in 
agreement to the initial target of my PhD. It would be interesting to extend these study to further 
investigations within the formulation field in the pharmaceutical and agrochemical industry. Indeed, 
the synthesis of new materials by adopting the principles of synthesis of green chemistry is an 
important aspect, as respect for the environment is fundamental in order to produce innovative and 
sustainable crystalline forms on a large-scale. Accordingly, the studies carried out during my PhD 
can be a stimulus to introduce innovative methods in the formulation field simplifying the 
conventional industrial processes (using a small number of excipients) and changing the physical-
chemical properties with respect to the current formulations. 
 
